

1 **Title**

2 Prolonged T cell – DC macro-clustering within lymph node microenvironments initiates Th2 cell
3 differentiation in a site-specific manner

4
5 **Authors**

6 Miranda R. Lyons-Cohen¹, Elya A. Shamskhou¹, Michael Y. Gerner^{1*}

7
8 ¹ Department of Immunology, University of Washington School of Medicine, Seattle, WA, USA

9
10 *Corresponding author:

11
12 Michael Y. Gerner

13 Email: gernermy@uw.edu

14 Address: 750 Republican Street Seattle, WA 98109

15 Phone: 206-685-3610

16
17
18 **Summary (150 words)**

19 Formation of T helper 2 (Th2) responses has been attributed to low-grade T cell stimulation, yet how large-
20 scale polyclonal Th2 responses are generated *in vivo* remains unclear. Here, we used quantitative imaging
21 to investigate early Th2 differentiation within lymph nodes (LNs) following cutaneous allergen
22 administration. Contrary to current models, Th2 differentiation was associated with enhanced T cell
23 activation and extensive integrin-dependent ‘macro-clustering’ at the T-B border, which also contrasted
24 clustering behavior seen during Th1 differentiation. Unexpectedly, formation of Th2 macro-clusters within
25 LNs was highly dependent on the site of skin sensitization. Differences between sites were driven by
26 divergent activation states of migratory cDC2 from different dermal tissues, with enhanced costimulatory
27 molecule expression by cDC2 in Th2-generating LNs promoting T cell macro-clustering and cytokine
28 sensing. Thus, generation of dedicated priming micro-environments through enhanced costimulatory
29 molecule signaling initiates the generation of Th2 responses *in vivo* and occurs in a skin site-specific
30 manner.

31

32 Introduction

33 Upon activation, naïve CD4 T cells differentiate into distinct helper cell lineages with specific effector
34 functions tailored to eliminate different classes of pathogens. Th2 cells provide defense against parasitic
35 helminth infections and promote tissue repair, but when inappropriately activated, can cause allergic
36 disease or asthma¹. Much work has gone into understanding the cellular and molecular mechanisms
37 driving early Th2 differentiation, collectively resulting in the quantitative and qualitative models, which
38 are also somewhat divergent from how other T helper cell lineages are thought to be generated^{2,3}.

39

40 The quantitative model posits that the signal strength sensed during initial T cell activation is a major
41 factor regulating T helper cell polarization. Th2 differentiation has been suggested to involve decreased T
42 cell receptor (TCR) signaling, either through reduced TCR affinity, lower levels of peptide MHC (pMHC)
43 complexes presented by antigen presenting cells (APCs), or through limited sensing of costimulatory
44 molecules²⁻⁴. Reduced signaling is thought to decrease the longevity of T cell – DC interactions, thus
45 minimizing the ability of T cells to respond to inflammatory cytokines from DCs and ultimately promoting
46 an endogenous program of Th2 polarization^{2,5,6}. Confounding this model however is the notion that
47 generally all *in vivo* responses involve polyclonal T cell populations with diverse TCR affinities, yet Th2 cells
48 are not generated in all inflammatory contexts. Additionally, enhanced exposure to costimulatory
49 molecules has been positively and not negatively associated with Th2 differentiation⁷⁻¹². It is also not clear
50 how low-grade stimulation elicits large scale *in vivo* Th2 responses as observed during helminth or allergen
51 exposure, especially given that both result in maturation of cDCs and significant costimulatory molecule
52 expression¹³⁻¹⁶.

53

54 In addition to quantitative signal strength -based factors, qualitative sensing of polarizing cytokines is
55 important for T cell differentiation *in vivo*. However, unlike other helper cell lineages, Th2-promoting
56 cytokines do not appear to operate in a typical ‘signal 3’ fashion through production by APCs¹⁷. Interleukin
57 (IL) -4 is critical for Th2 differentiation both *in vitro* and *in vivo*, but this cytokine is not produced by cDCs
58 and the exact cellular source/s of IL-4 in LNs remains ill-defined^{1,17}. Notably, recently activated T cells can
59 produce IL-4 after TCR stimulation independently of the Th2 lineage-defining transcription factor, Gata3,
60 and it has been suggested that paracrine delivery of IL-4 between activated T cells is sufficient for Th2
61 differentiation¹⁸⁻²¹. Similarly, T cell derived IL-2, also produced downstream of T cell activation, is
62 necessary for Th2 response formation *in vivo*^{21,22}, and this cytokine is again delivered via paracrine
63 exchange between activated T cells and not provided by APCs^{23,24}.

64
65 Moreover, not all cDC populations have equivalent capacities to induce Th2 responses. Following barrier
66 tissue damage, locally released alarmins induce the activation of cDC2s, including cells expressing CD301b
67 and variegated levels of Sirp α /CD11b expression^{13,14,25}. Activated cDC2s in turn migrate into draining LNs,
68 where they can induce Th2 responses^{13,14,25-30}. cDC2s, however, are also highly plastic and based on the
69 nature of the stimulus can generate diverse helper lineages, including T follicular helper (Tfh), Th1, and
70 Th17 cells³¹⁻³⁴, and the exact molecular mechanisms of how these cells promote Th2 responses during
71 type-II inflammation remain unknown. cDC1s on the other hand constitutively secrete IL-12 and inhibit
72 Th2 responses, instead promoting Th1 and CD8 T cell immunity^{35,36}. Optimal Th2 differentiation thus likely
73 involves both selective engagement with appropriately activated cDC2 and avoidance of cDC1
74 populations. How such selectivity is achieved *in vivo* is unknown, although recent quantitative imaging
75 studies demonstrated that different cDC subsets are non-equivalently spatially distributed within LNs,
76 which could allow for preferential engagement vs. avoidance of specific DC subsets by responding T cells
77 in distinct tissue compartments³⁷. Indeed, during type-I inflammation, the spatial positioning of specific
78 innate subsets, including monocytes and activated cDCs, establishes the formation of dedicated
79 microenvironments in the deep T cell zone to generate effector Th1 and CD8 T cell responses^{38,39}. In
80 contrast, CD301b⁺ cDC2s predominantly localize at the T/B border, a location where early Th2 cells have
81 also been previously noted^{25,40-42}. This suggests an additional underexplored spatial component of Th2
82 differentiation in which LN microenvironments populated by appropriately instructed myeloid subsets
83 drive T cell differentiation towards distinct helper lineages.

84
85 Here, we used quantitative microscopy to investigate the early stages of *in vivo* Th2 differentiation after
86 cutaneous administration of the allergen, papain, and other type-II stimuli, as well as compared these
87 responses to Th1 differentiation with TLR agonist immunization. In contrast to the predicted limited
88 cellular activation in Th2 settings, we observed enhanced T cell signaling and extensive clustering, here
89 termed ‘macro-clustering’, of early differentiating Th2 cells which primarily occurred near the T-B border
90 of the LN paracortex. Macro-clustering was integrin-mediated and was associated with enhanced local
91 cytokine signaling, suggesting that the spatial proximity of activated T cells enabled optimized cytokine
92 exchange for Th2 differentiation. Enhanced T cell signaling and macro-clustering were also distinct from
93 that seen with adjuvant induced Th1 responses. Surprisingly, formation of Th2 responses was highly
94 dependent on the specific skin site of type-II agonist administration, with footpad-delivered stimuli
95 eliciting markedly reduced Th2 responses as compared to other skin sites, but without compromised

96 ability to elicit Th1 differentiation across different tissues. Th2 differentiation in LNs was driven by
97 migratory cDC2s, and the observed site specific generation of Th2 responses enabled a direct comparison
98 of key cDC2 properties necessary for Th2 differentiation using the same agonist. This revealed divergent
99 activation states for migratory cDC2 emigrating from different skin sites and a critical role for enhanced
100 costimulatory molecule expression coupled with low levels of pMHC-II to drive T cell macro-clustering,
101 cytokine signaling, and Th2 differentiation. Collectively, our findings argue that enhanced costimulation
102 and integrin driven signaling coupled with low grade TCR stimulation promotes T cell macro-clustering
103 and generates LN microenvironments which drive Th2 response formation *in vivo*. Our data also support
104 the emerging notion that generation of T cell responses is heavily impacted by upstream barrier
105 tissues^{43,44}, raising fundamental questions on the mechanisms leading to divergent responses among skin
106 sites and having clear implications for allergic disease development.

107

108 **Results**

109 *Generation of Th2 microenvironments in skin draining LNs*

110

111 To examine the early processes governing *in situ* Th2 differentiation, we crossed Ovalbumin (OVA)-specific
112 TCR-transgenic OT-II mice to IL-4 mRNA reporters⁴⁵ to generate 4get-GFP OT-II mice (4get-GFP.OT-II) on a
113 CD45.2 congenic background. We then adoptively transferred naïve 4get-GFP.OT-II CD4 T cells into
114 CD45.1⁺ recipient B6 mice, administered papain plus OVA intradermally in the ear pinnae one day later,
115 and examined the localization and phenotype of activated OT-II cells in auricular (Au) draining LNs 2-3
116 days after immunization using quantitative multiparameter microscopy. Papain is a cysteine protease and
117 a clinically relevant allergen in humans and mice that drives robust induction of type-II immunity after
118 cutaneous administration²⁵. CD62L blocking antibody was also administered 6 hours after immunization
119 to minimize the impact of asynchronous activation of naïve T cells recruited into LNs late into the
120 response⁴⁶. We observed formation of extensive macro-clusters of OT-II cells located primarily at the T-B
121 border of draining LNs (Figure 1A), and the clustered cells expressed high levels of IRF4 and Ki67, indicative
122 of T cell activation and proliferation (Figure 1A, 1B region 1 inset). Cells within the clusters also expressed
123 high quantities of the Th2 lineage-defining transcription factor, Gata3, and were positive for the 4get-GFP
124 reporter signal, indicating IL-4 mRNA transcription. In contrast, fewer activated OT-II cells outside the
125 macro-clusters expressed Gata3 and 4get-GFP (Figure 1A, 1B region 2 inset), suggesting that the macro-
126 clusters represented regions where T cells underwent their earliest stages of Th2 lineage commitment
127 detectable with this approach. Large Th2 macro-clusters at the T-B border were also observed when

128 examining endogenous CD4 T cell responses after papain inoculation of 4get-GFP mice, indicating that
129 this macro-clustering phenomenon was occurring during polyclonal endogenous T cell activation, and was
130 not an artifact of high precursor frequency after adoptive transfer (Figure S1A). Moreover, macro-clusters
131 of IRF4, Gata3 and 4get-GFP-expressing polyclonal Th2 cells were also found in mesenteric LNs 6 days post
132 infection with the helminth *Nippostrongylus brasiliensis* (N.b.), a timepoint when the parasite establishes
133 robust infection in the intestine and induces Th2 priming⁴⁷ (Figure S1B).

134
135 As a comparison, we examined responses after OVA plus CpG immunization, which promotes Th1
136 differentiation³⁸. CpG OVA immunization elicited robust OT-II activation and proliferation indicated by
137 Ki67 expression, but these T cells had undetectable Gata3 and 4get-GFP expression, corresponding to lack
138 of Th2 differentiation in these settings (Figure 1C). In contrast to papain induced responses, CpG
139 immunization did not elicit the formation of dense T cell macro-clusters and instead generated much
140 smaller cell clusters which were more diffusely distributed throughout the T cell zone and the outer LN
141 paracortex, consistent with past findings on behavior of CD4 T cells during Th1 differentiation^{38,39} (Figure
142 1C-D).

143
144 Previous studies visualizing IL-4 producing cells in LNs at late time points have been conflated by detection
145 of IL-4 producing Tfh cells within B cell follicles^{48,49}, so we examined Tfh markers on the responding 4get-
146 GFP⁺ T cells 2-3 days after papain OVA treatment. We found that most of the 4get-GFP⁺ cells displayed
147 high levels of the high affinity IL-2 receptor, CD25, and low levels of CXCR5 and PD-1 staining (Figure S1C),
148 indicating early effector T cell and not Tfh differentiation⁵⁰⁻⁵². Similarly, endogenous activated
149 (CD44⁺Ki67⁺) Gata3⁺ CD4 T cells expressed CD25 and lacked BCL6 expression, while a separate population
150 of CD25^{neg} cells co-expressed Gata3 and BCL6, indicating bifurcation of effector lineages (Figure S1D)⁵³⁻⁵⁶.
151 To verify that IL-4 mRNA competent 4get-GFP⁺ T cells also produced IL-4 protein, we examined responses
152 in KN2^{+/-} reporter mice which express human CD2 (huCD2) on the surface of T cells actively producing IL-
153 4 protein⁵⁷. We found abundant huCD2 expression on endogenous responding Gata3⁺ CD44⁺Ki67⁺ CD4 T
154 cells suggesting active IL-4 protein production (Figure S1E).

155
156 To investigate which specific myeloid cell population/s were associated with the Th2 macro-clusters, we
157 next co-stained sections of papain-immunized auricular draining LNs with various innate cell markers and
158 used histo-cytometry and CytoMAP to analyze myeloid cell composition and distribution^{42,58}.
159 Neighborhood clustering analysis identified distinct LN regions populated by different myeloid cell subsets

160 (Figure 1E-G). As previously reported, migratory cDC2s, including CD11b⁺CD301b⁺ and CD11b⁺CD301b^{neg}
161 subsets were predominantly localized in the outer T zone regions, with CD301b⁺ cDC2s localized at the T-
162 B border and in close proximity to the Th2 macro-clusters^{25,40,59} (Figure 1E). In contrast, CD11b⁺CD207⁺
163 Langerhans cells were predominantly distributed within the deeper T cell zone and appeared spatially
164 segregated from the Th2-dense regions (Figure 1E-G). CytoMAP spatial correlation analysis across multiple
165 LNs confirmed these observations, demonstrating that CD301b⁺ cDC2s were the dominant myeloid cell
166 subset spatially correlated with Th2 cells, while neighborhood clustering identified distinct regions with
167 preferential CD301b⁺ cDC2s and Th2 enrichment (Figure 1F-H). Together these data demonstrate the
168 formation of Th2 microenvironments defined by macro-clustering of early differentiating Th2 cells and
169 migratory cDC2 subsets.

170
171 cDC2s have been previously demonstrated to drive Th2 polarization, but not T cell proliferation, after
172 papain immunization^{25,60}. To examine the requirement of migratory cDC2s for Th2 responses in our model,
173 we examined OT-II cell responses in IRF4^{fl/fl} CD11c-Cre⁺ mice which exhibit impaired cDC2 migration from
174 peripheral tissues into LNs, while keeping other cDC populations intact^{27,30} (Figure S1F). Indeed, as
175 compared to Cre^{neg} littermate controls, loss of migratory cDC2 in IRF4^{fl/fl} CD11c-Cre⁺ animals significantly
176 reduced Gata3 and IRF4 expression in the responding OT-II cells without altering their clonal expansion,
177 suggesting abrogated Th2 differentiation but not priming (Figure 1I). cDC2s have also been reported to
178 promote Tfh differentiation^{31,32,61}, and we noted reduced BCL6 expression in responding CD44⁺ Gata3^{neg}
179 OT-II cells in IRF4^{fl/fl} CD11c-Cre⁺ mice (Figure 1I), suggesting that migratory cDC2s mediate the initiation of
180 both Th2 and Tfh responses. Altogether, these data indicate that cutaneous papain administration into
181 the ear pinnae induces the formation of Th2-promoting microenvironments at the T-B border composed
182 of macro-clusters of highly activated, early differentiating Th2 cells and CD301b⁺ migratory cDC2s, which
183 drive Th2 response induction, and that this clustering behavior is also distinct from that observed during
184 Th1 differentiation after TLR agonist immunization.

185
186 *Th2 macro-clustering and differentiation is site-specific*

187
188 Cutaneous exposure to allergens and associated antigens can occur in distinct anatomical locations.
189 Surprisingly, when administering papain OVA into distinct skin sites, we observed major differences in Th2
190 response induction within the corresponding skin draining LNs. As above, auricular LNs draining ear pinnae
191 generated extensive early Th2 macro-clustering at the T-B border (Figure 2A). In contrast, the equivalent

192 dose of papain and antigen administered in the footpad led to minimal Th2 differentiation in the draining
193 brachial (Br) LNs (Figure 2B-C). Instead of macro-clustering at the T-B border, most OT-II T cells in brachial
194 LNs were more homogenously distributed and localized in smaller clusters throughout the T cell zone, and
195 expressed significantly less Gata3 and 4get-GFP as detected by histo- and flow cytometry (Figure 2A-E).
196 Decreased Th2 response formation was not due to general lack of T cell activation, as following footpad
197 immunization brachial LN OT-II T cells expressed abundant Ki67 and underwent equivalent or even greater
198 levels of early proliferation as compared to those in auricular draining LNs (Figure 2B, E).

199
200 Site-specific differences between the ear and footpad were maintained for at least 6 days and across
201 peripheral organs, with significantly reduced frequencies of effector Th2 OT-II cells also found in the
202 parenchyma of the lung and spleen, suggesting that divergent T cell responses were maintained even after
203 OT-II cells migrated out of the original site of priming (Figure 2F-G). Despite the similar initial clonal bursts,
204 by day 6, OT-II cells primed in auricular draining LNs exhibited increased expansion as compared to those
205 primed in brachial draining LNs and greater numbers of OT-II cells disseminated to the spleen and lungs
206 (Figure 2G). At these later time points, the auricular draining LNs also exhibited increased frequency of
207 CXCR5⁺PD-1⁺ Tfh OT-II cells, and the cells also expressed a greater amount BCL6, suggesting that both Th2
208 and Tfh responses were linked to the specific skin site of immunization (Figure S2A). Site-specific Th2
209 differences were also observed for endogenous CD4 T cells in KN2^{+/-} reporter mice, with a significant
210 reduction of IL-4 producing Gata3⁺ CD4 T cells in footpad draining brachial LNs (Figure S2B). Th2 response
211 differences across immunization sites were also observed in Balb/c mice, indicating that this phenomenon
212 was conserved across mouse strains with differential abilities to drive type-II immunity⁶² (Figure S2C), as
213 well as after OVA Alum immunization in endogenous T cell and OT-II settings (Figure S2D-E). We next
214 examined Th1 differentiation settings after CpG OVA immunization in distinct cutaneous tissues. In stark
215 contrast to type-II inflammation settings, CpG OVA resulted in equivalent expansion, Tbet expression, and
216 CXCR3 expression in responding OT-II cells in both auricular and brachial LNs, indicating comparable Th1
217 response formation between the different sites (Figure 2E). Equivalent Th1 responses across these distinct
218 LNs were also previously observed with other type-I adjuvants³⁸.

219
220 Non-equivalent Th2 responses in different skin draining LNs may result from intrinsic differences between
221 the LNs, differential lymphatic drainage of antigens and agonists, or fundamental differences in how
222 distinct cutaneous sites program local immune responses. To investigate whether brachial LNs have an
223 inherent defect in mounting Th2 immunity, we immunized mice with papain OVA in the dorsal skin of the

224 flank, which targets a different skin dermatome but antigen and agonist also drain into brachial LNs.
225 Although generating more heterogeneous responses as compared to footpad inoculation, likely due to
226 more diffuse agonist dispersal across the subcutaneous tissue compartment, flank injection resulted in
227 relatively normal Th2 induction in brachial LNs, which was more analogous to that found in auricular LNs
228 with ear immunization (Figure S2F-G). We also tested other cutaneous sites, including the hind paw and
229 the tail base which drain the popliteal and inguinal LNs, respectively. Similar to brachial LN responses with
230 forepaw injection, hind paw inoculation also elicited limited Th2 responses in the draining popliteal LNs,
231 with decreased Gata3 expression by activated OT-II cells. In contrast, tail base administration of papain
232 OVA generated heightened Th2 responses within the inguinal draining LNs (Figure S2F-G). We next
233 examined whether site-specific Th2 response differences would be maintained in a model which does not
234 involve abundant lymphatic drainage induced by injection. For this, we painted the ear vs. footpad skin
235 with dibutyl phthalate (DBP) to induce a model of Th2-driven contact hypersensitivity in which antigen
236 and adjuvant are administered epicutaneously and not intradermally⁶³. Although DBP painting did not
237 induce as potent of proliferative responses as papain injection, major differences in Th2 differentiation
238 were still observed across the draining LNs, with markedly increased Gata3 and IRF4 expression in
239 responding CD4 T cells within auricular but not brachial draining LNs (Figure S2H).

240
241 Together, these findings indicate that distinct cutaneous sites have non-equivalent abilities to drive Th2
242 macro-clustering and Th2 differentiation, but that these site-specific differences do not necessarily extend
243 to other helper cell lineages, such as Th1 responses. Moreover, non-equivalent responses between sites
244 do not simply result from intrinsic differences between the lymphoid organs or are restricted to injection-
245 based models, indicating a more generalizable divergence in the ability to drive Th2 responses across
246 distinct skin sites.

247
248 *Costimulatory molecule expression is enhanced on migratory cDC2s derived from auricular LNs*

249
250 Given the critical role of cDC2s in driving Th2 responses, we next examined the hypothesis that migratory
251 cDC2 responses were non-equivalent for the distinct dermal tissues. To test this, we immunized mice with
252 papain plus the fluorescent protein E α GFP into the forepaw or ear pinnae⁶⁴, and examined antigen-
253 bearing migratory DCs in the corresponding draining LNs. Albeit some variation was observed among
254 individual samples, across multiple experiments we found no major differences in the number of total
255 cDC2s, antigen-bearing E α GFP⁺ cDC2s, or in the amount of E α GFP captured by these cells between the

256 sites (Figure 3A-C, S3A). The dominant antigen-bearing population in both draining LNs were the CD301b⁺
257 cDCs (Figure S3B), and their total number did not differ between draining LNs (Figure 3C). The overall
258 composition of antigen-bearing cells was also largely similar across the LNs, albeit a modest increase in
259 the frequency of antigen-bearing CD301b⁺ DCs and CD64⁺ cells and a corresponding decrease in
260 CD301b^{neg}CD11b^{neg} DCs in brachial LNs was noted (Figure S3B).

261

262 We also examined the amount of pMHC-II complex presented on the cDC surface using the Y-Ae antibody,
263 which recognizes the E α peptide presented on I-Ab⁶⁴. Surprisingly, we found that while papain induced
264 robust antigen uptake by migratory cDCs, this was not associated with detectable pMHC-II complex on
265 the cell surface (Figure S3C-D). Minor differences in the total number, but not frequency, of E α GFP⁺ Y-Ae⁺
266 migratory DCs were noted between auricular and brachial LNs after papain immunization (Figure S3D). In
267 contrast to papain settings, E α GFP plus CpG immunization elicited both antigen uptake and robust surface
268 pMHC-II expression by migratory cDCs (Figure S3C-D), demonstrating major differences in how type-I and
269 type-II stimuli impact MHC-II antigen processing and presentation and suggesting that during *in vivo* type-
270 II responses to papain, surface pMHC-II expression is relatively limited on migratory DCs. Of note, E α
271 peptide sequence analysis did not identify papain cleavage sites, indicating that the divergence in pMHC-
272 II complex between papain and CpG conditions was not simply a result of protease mediated degradation
273 of the E α peptide.

274

275 To further interrogate potential differences among migratory cDCs from different cutaneous sources, we
276 next sorted antigen-bearing (E α GFP⁺) migratory cDC2 subsets (MHC2^{Hi}CD11c^{Int} CD301b^{+/neg}CD11b^{+/neg})
277 from auricular and brachial dLNs two days post papain plus E α GFP immunization, or from naïve mice, and
278 performed bulk RNA sequencing. As expected, principal component analysis (PCA) of all samples
279 demonstrated that the primary segregation was driven by the immunization state, with samples clustering
280 based on whether they were obtained from naïve or papain immunized LNs, revealing large-scale
281 transcriptional changes across all cDC populations from both tissues after papain immunization (Figure 3D
282 left, S3E-F). Of note, IL-12b, which is constitutively expressed by migratory cDCs at steady state^{35,36}, was
283 downregulated upon papain immunization (Figure S3F). When considering only the papain immunized
284 samples, further PCA separation demonstrated that sample divergence on the PCA1 axis was dominantly
285 driven based on the specific LN of origin, indicating major transcriptional differences between the antigen-
286 bearing auricular-derived and brachial-derived cDCs, while also maintaining a secondary level grouping
287 along the PCA2 axis based on the cell subset (Figure 3D right, S3E). Of the top 100 differentially expressed

288 genes (DEGs) between sites, DCs from auricular LNs preferentially upregulated genes associated with
289 activation and costimulation including CD80, CD86, PDL1, and PDL2, indicating increased cDC2 maturation
290 (Figure 3E-F). Divergent expression of these molecules at the protein level was confirmed by flow
291 cytometry, demonstrating that antigen-bearing migratory cDC2s in auricular LNs following ear pinnae
292 immunization expressed significantly higher levels of CD80 and CD86 costimulatory molecules as
293 compared to their antigen-bearing counterparts from brachial LNs following footpad immunization
294 (Figure 3G-H). We also noted increased expression of PD-L1 and PD-L2 on auricular-derived cDC2s at the
295 protein level (Figure S3G). In several subsets, cDC2 gene signatures in brachial LNs were also enriched in
296 type 1 interferon (IFN) and viral sensing pathways such as expression of the interferon-stimulated gene,
297 MX1, suggesting that additional differences exist between the sites (Figure 3F, S3H). In contrast, auricular
298 gene signatures were enriched in cytokine-mediated and leukocyte proliferation signaling pathways.
299 Together, these data suggest that while being relatively similar prior to inflammation, cDC2s migrating
300 into LNs from different cutaneous sites exhibit marked differences at the transcriptional and protein
301 levels, and in particular for costimulatory molecule expression.

302

303 *Site-specific T cell response differences are mediated through non-equivalent expression of costimulatory*
304 *molecules by migratory cDCs.*

305

306 Costimulation synergizes with TCR signaling to drive optimized T cell activation and has been implicated
307 in Th2 differentiation^{4,7-11,65,66}. Given the costimulatory molecule expression differences on DCs between
308 the sites, we investigated whether activation of signaling pathways downstream of TCR and costimulation
309 were also nonequivalent in activated T cells in different draining LNs. Indeed, we found significantly higher
310 expression of the AP-1 transcription factors, BATF and IRF4, in activated OT-II T cells within the ear draining
311 auricular LNs, indicating non-equivalent engagement of the TCR / costimulatory molecule signaling
312 platform (Figure 4A-B, 2A-B). Expression of the transcription factors BATF and IRF4 in T cells has been
313 previously associated with Th2 differentiation and IL-4 production⁶⁷⁻⁷⁵, and we observed a strong positive
314 correlation of these molecules with each other and Gata3 and 4get-GFP expression (Figure 4C). Image-
315 based analysis also demonstrated increased phosphorylation of the mTOR signaling protein S6 (pS6), also
316 downstream of TCR / costimulation platform, in T cells within auricular draining LNs (Figure 4D).
317 Unexpectedly, in contrast to type-II inflammation, CpG OVA immunization promoted overall reduced
318 levels of pS6 and IRF4 as compared to papain within auricular LNs, and equivalent site-specific expression
319 across both LN sites (Figure 4A, D). This indicates that Th2 differentiation is associated with relatively

320 enhanced and not reduced T cell activation, and that site specificity in T cell response induction does not
321 extend to all T helper cell lineages.

322
323 Together, these findings suggested that after papain immunization, monoclonal CD4 T cells within ear
324 draining auricular LNs experienced increased overall stimulation compared to forepaw draining brachial
325 LNs. While being consistent with differential expression of costimulatory molecules by migratory cDC2s,
326 and with otherwise limited differences in the number and composition of antigen-bearing migratory cDCs
327 across the sites, it was still possible that insufficient delivery of antigen to brachial LNs after paw
328 immunization was mediating the reduced T cell activation and Th2 programming in this compartment. To
329 test this possibility, we titrated the amount of OVA administered into the skin sites along with a fixed
330 concentration of papain. Although increasing the OVA dose at each site up to 10x the original amount did
331 increase OT-II clonal expansion in both draining LNs, this did not enhance Th2 responses in brachial LNs,
332 suggesting that the total amount of antigen was not a limiting factor in driving reduced Th2 differentiation
333 after footpad immunization (Figure 4E). Of note, increased antigen delivery also did not elicit increased
334 Tbet expression in responding T cells, indicating that high antigen dose availability does not necessarily
335 promote Th1 skewing in papain immunization settings (Figure 4E).

336
337 Based on the above observations, we next directly tested the requirements for costimulatory molecule
338 expression on Th2 differentiation *in vivo*. For this, we performed a timed blockade of CD28 by
339 administering an anti-CD28 antibody 24 hours post immunization and harvesting LNs 24 hours later.
340 Delayed anti-CD28 administration allows the T cells to mount initial cognate interactions with cDCs for
341 early priming and activation, but would limit the prolonged costimulatory contacts during the
342 differentiation phase⁵. Indeed, delayed CD28 blockade resulted in very modest reductions of OT-II
343 cellularity, indicating relatively normal initial activation (Figure 5A), but markedly decreased the
344 expression of 4get-GFP, Gata3, BATF, and pS6 in both auricular and brachial LNs (Figure 5A-C). Delayed
345 CD28 blockade also resulted in reduced macro-cluster formation within auricular LNs, instead driving
346 more homogeneous and non-clustered distribution of OT-II cells throughout the T zone, akin to responses
347 observed in footpad draining brachial LNs (Figure 5B, D). Given that costimulation is thought to promote
348 general T cell activation for all helper cell lineages, we next tested whether prolonged costimulatory
349 sensing was important in Th1 inducing settings after CpG OVA immunization. Delayed CD28 blockade
350 elicited much more modest effects on CXCR3 and Tbet expression (Figure S5A), overall indicating that
351 prolonged costimulation was less essential in Th1-inducing settings.

352

353 To examine if increasing costimulation can directly modulate Gata3 expression and Th2 differentiation *in*
354 *vitro*, we next cultured naïve OT-II T cells in non-polarizing culture conditions with varying concentrations
355 of plate-bound anti-CD3 and anti-CD28 for 48 hours. We found that increasing the concentration of
356 available CD28 significantly enhanced Gata3 expression in T cells, and this was particularly evident at low
357 anti-CD3 concentrations (Figure 5E-G). IRF4 was also increased in a CD28-dependent manner, indicating
358 that this transcription factor can be regulated by both TCR and costimulation (Figure 5E-F). Additional
359 blockade of IFN- γ further increased Gata3 expression across both low and intermediate anti-CD3 culture
360 conditions, supporting its role in suppressing Th2 cell differentiation (Figure 5F-G). Moreover, dose-
361 dependent CD28-mediated effects on Gata3 expression were also observed in Th2-polarizing culture
362 conditions, albeit Gata3 and IRF4 expression was significantly greater than in non-polarizing settings
363 (Figure S5B). Together, these data suggest that costimulation can directly enhance T cell activation and
364 Th2 differentiation by inducing IRF4 and Gata3 expression, and that differences in T cell differentiation
365 across the distinct skin draining LNs are most likely driven by non-equivalent expression of costimulatory
366 molecules by migratory cDC2s.

367

368 *Th2 macro-clustering and differentiation is driven by prolonged ICAM1-mediated DC-T cell contacts*

369

370 The above findings indicated that T cell macro-clustering was dependent on prolonged costimulatory
371 molecule availability from migratory cDC2s (Figure 5B). We next tested how prolonged T cell – DC contacts
372 were mediated *in vivo*. The LFA-1 integrin is rapidly upregulated on T cells following activation, and its
373 ligand, ICAM-1, is expressed on DCs after maturation to mediate T cell – DC interactions^{46,76}. LFA-1 has
374 also been shown to reduce the threshold of TCR / costimulatory signaling required for T cell activation
375 thus enabling increased activation in setting of low pMHC-II⁷⁷. We observed marked ICAM-1 upregulation
376 on activated antigen-bearing E α GFP⁺ migratory DCs in both brachial and auricular LNs, and this was also
377 elevated as compared to ICAM-1 expression after CpG immunization (Figure 6A). To test if T cell macro-
378 clustering and Th2 differentiation was mediated via prolonged integrin-driven T – DC interactions, we
379 performed a delayed LFA-1 blockade, treating mice with an anti-LFA-1 blocking antibody 24 hours post
380 papain OVA administration and examining responses in auricular and brachial LNs 24 hours later^{46,78}.
381 Delayed LFA-1 blockade did not markedly alter OT-II T cell proliferation, indicating relatively normal initial
382 activation (Figure 6C). In contrast, 4get-GFP, Gata3, and IRF4 expression were all significantly decreased
383 in draining LNs after delayed LFA-1 blockade, indicating reduced Th2 differentiation (Figure 6B-C, E). LFA-

384 1 blockade also disrupted the T cell macro-clustering at the T-B border, indicating limited formation of
385 Th2 microenvironments (Figure 6D, F). In contrast to type-II inflammatory settings, delayed LFA-1
386 blockade had a minimal effect on Th1 differentiation after OVA CpG immunization (Figure S6A-B),
387 suggesting that prolonged LFA-1 integrin mediated cell interactions are less important in these settings.

388

389 After activation, T cells can also express ICAM-1 on the cell surface, and in addition to T – DC interactions
390 could potentially engage in homotypic T - T cell contacts⁴⁶. To dissect whether delayed LFA-1 blockade
391 was primarily affecting T - DC or T - T cell interactions, we generated ICAM1.KO OT-II cells (Figure S6C) and
392 compared these responses to WT OT-II cells. In these experimental settings, ICAM1.KO OT-II T cells retain
393 normal LFA-1 integrin functionality and can interact with ICAM1-expressing cDCs but lack the ability to
394 engage in homotypic T - T cell contacts. We found no defects in Th2 differentiation in ICAM-1 deficient
395 OT-II T cells, indicating that LFA-1 / ICAM-1 mediated homotypic T - T interactions are not required for
396 early Th2 responses (Figure S6D). Together, these data suggest that enhanced T cell activation via
397 costimulatory molecules expressed by cDCs promotes prolonged LFA1 integrin-mediated T - DC
398 interactions within auricular ear draining LNs, and these contacts in turn drive the formation of T cell
399 macro-clusters and promote Th2 differentiation.

400

401 *Increased costimulation in auricular draining LNs promotes enhanced cytokine signaling and Th2*
402 *differentiation*

403

404 Costimulation promotes the production of IL-2 by activated T cells, as well as can elicit the production of
405 the Th2 cytokine IL-4 *in vitro*^{4,7-11,65,66}. IL-2 signaling in turn increases expression of the IL-4 receptor, IL-
406 4R α , such that IL-2 stimulated T cells become more receptive to IL-4⁷⁹. T cell costimulation and macro-
407 clustering may thus promote increased local bioavailability of the cytokines IL-2 and IL-4, produced
408 directly by activated T cells, which may reinforce localized Th2 differentiation within the macro-clusters.
409 Indeed, we found CD25 was highly expressed on the activated CD44⁺ Gata3⁺ OT-II Th2 cells (Figure 7A).
410 Further, early Gata3⁺CD25⁺ Th2 cells had increased expression of phosphorylated (p)STAT5 and pSTAT6,
411 indicating enhanced and/or sustained IL-2 and IL-4 signaling, respectively, as compared with
412 Gata3^{neg}CD25^{neg} non-Th2 cells (Figure 7B).

413

414 Consistent with non-equivalent T cell activation and differentiation in different draining LNs, both pSTAT5
415 and pSTAT6 in responding OT-II cells were significantly elevated in auricular as compared to brachial

416 draining LNs (Figure 7C). pSTAT levels were also directly correlated with non-equivalent GATA3 expression
417 across the sites (Figure 7D), suggesting direct involvement in Th2 differentiation. We thus tested whether
418 differential sensing of costimulatory molecules by the responding T cells in distinct draining LNs resulted
419 in non-equivalent cytokine signaling and Th2 differentiation. For this, we again utilized the timed CD28
420 blockade and examined phosphorylation of STAT5 and STAT6 molecules 24 hours later. Indeed, we found
421 that delayed anti-CD28 treatment significantly reduced pSTAT5 and pSTAT6 expression in auricular
422 draining LNs, and completely abrogated the differences between the tissues (Figure 7E-F). Similar effects
423 were observed after *in vivo* anti-IL-2 blockade, and both anti-CD28 and anti-IL-2 treatments resulted in
424 comparable decreases in STAT5, and to a lesser extent STAT6, phosphorylation (Figure 7E-F). Finally, both
425 anti-CD28 and IL-2 blockade markedly reduced Gata3 expression in responding OT-II cells indicating a clear
426 link between prolonged costimulation, cytokine sensing, and Th2 differentiation (Figure 7F). In sum, our
427 data indicate that increased sensing of costimulatory molecules by early differentiating T cells in ear
428 draining auricular LNs is associated with enhanced T cell macro-clustering, increased local IL-2 and IL-4
429 cytokine production and sensing, and amplified early Th2 differentiation (Figure S7).

430

431 Discussion

432 *In vivo* mechanisms driving early Th2 differentiation in LNs have remained enigmatic, in large part due to
433 the complex role of TCR signaling in directing T cell effector fates and the lack of clear understanding of
434 which molecules expressed by cDCs, or other innate cells in LNs, selectively induce Th2 polarization²¹. Our
435 studies indicate that early differentiating Th2 cells undergo enhanced T cell signaling and activation, and
436 that this is mediated through macro-clustering at the T-B border with migratory cDC2s displaying high
437 levels of costimulatory molecules and integrin ligands but relatively low levels of surface pMHC. This in
438 turn appears to promote efficient cytokine exchange, in particular for IL-2 and IL-4, among neighboring
439 activated T cells to reinforce localized Th2 differentiation and to support prolonged proliferation. Thus,
440 formation of discrete spatial microenvironments within LNs in which T cells integrate quantitatively strong
441 activation signals from cDC2s coupled with qualitative cytokine sensing from nearby T cells promotes the
442 initiation of large-scale Th2 responses *in vivo*.

443

444 Past studies have demonstrated that *in vitro* stimulation of CD4 T cells with strong TCR agonists or high
445 dose of peptide promotes Th1 differentiation, while low dose signals elicit Th2 differentiation^{2,3}. This has
446 also been supported by *in vivo* work using peptide-pulsed DCs, which showed that TCR signal strength

447 serves as a rheostat to control cytokine receptor expression, in turn modulating the ability of T cells to
448 sense cytokines and undergo T helper cell differentiation²⁻⁴. Our studies are consistent with this hierarchy
449 model, showing that cells undergoing the greatest degree of activation also receive abundant cytokines
450 and thus become more differentiated. However, we show that during *in vivo* allergen exposure, prolonged
451 and enhanced T activation leads to Th2 and Tfh, not Th1 polarization, and that Th1 differentiation occurs
452 at minimal rates for these responses regardless of antigen dosage. Differences in these observations are
453 likely explained by the fact that environmental allergens such as papain elicit inflammatory functions via
454 proteolytic disruption of the epithelial barrier and release of the alarmin IL-33⁸⁰, and this in turn induces
455 cDC maturation and costimulatory molecule expression through local type 2 innate lymphoid cell (ILC2)
456 activation^{13,14,81,82}, thus necessitating *in vivo* administration to appropriately instruct cDCs. In addition, we
457 and others show that during type-II inflammation, cDCs have a reduced capacity to produce the type-I
458 skewing cytokine IL-12, thus minimizing the capacity of T cells to undergo Th1 differentiation^{34,38}. Further,
459 activated T cells displaying high levels of cytokine receptors appear confined within microenvironments
460 rich in other T cells and cDC2s and away from other potential cellular sources of IL-12, which could
461 suppress early Th2 differentiation^{35,36}. In this regard, we previously showed that papain administration
462 does not elicit robust monocyte recruitment to the draining LNs³⁸, as these cells can also produce copious
463 amounts of IL-12 during type-I inflammation⁸³. Altogether, these findings suggest there is limited
464 availability of Th1 inducing factors in draining LNs after papain administration, indicating that highly
465 activated T cells undergoing prolonged interactions with cDCs receive Th2 polarizing cytokines in the
466 absence of Th1-promoting factors, leading to the generation of large-scale Th2 responses. Notably,
467 prolonged costimulatory signaling and formation of T cell macro-clusters appears far less critical for Th1
468 responses *in vivo*. This may be due to comparatively lower expression of integrin ligands by cDC2s to
469 mediate prolonged clustering, high abundance of inflammatory cytokines across vast regions of the LN
470 parenchyma, and presence of chemokines which would drive CXCR3-expressing early Th1 cells away from
471 sites of initial T – DC contacts^{38,39}.

472
473 Extensive evidence now exists that migratory cDC2s are required for Th2 differentiation²⁵⁻³⁰. We similarly
474 find that ablation of cDC2 migration from the skin abrogates Th2, as well as Tfh, differentiation in LNs,
475 albeit not necessarily at the cost of reduced early T cell priming. This may be explained by the fact that in
476 settings of ample antigen drainage, lymph node resident cDCs initiate early T cell proliferation, while
477 migratory cDC2s induce downstream Th2 differentiation^{37,38,60}. Factors expressed by cDC2s to selectively
478 initiate Th2 skewing have remained unknown³⁴, but costimulatory molecule expression by cDCs can

479 promote type-II cytokine production by *in vitro* stimulated T cells⁷⁻¹². *In vivo*, TSLP-driven OX40L
480 costimulatory molecule expression by cDCs has been positively linked with Th2 responses^{14,15,84}.

481
482 Costimulatory molecules on their own do not constitute a Th2 polarizing stimulus and can be involved in
483 promoting general T cell activation. However, we find that prolonged costimulation was less essential for
484 adjuvant induced Th1 responses, indicating differential requirements of costimulation for distinct helper
485 cell lineages. Our data do support the notion that costimulation is essential for inducing IL-2 and IL-4
486 cytokine production by activated T cells^{18-21,85-87}, and likely for eliciting IL-4R α upregulation, in turn
487 allowing IL-2-experienced T cells to become more receptive to IL-4 signaling to drive enhanced Th2
488 differentiation⁷⁹. IL-2 also skews responding T cells away from the Tfh lineage, thus supporting additional
489 specification of helper cell fate^{51,55,56}. Conversely, the spatial proximity of macro-clusters near B cell
490 follicles could also directly support Tfh differentiation by enhancing the probability of interactions
491 between those activated T cells which receive less IL-2 and neighboring B cells presenting cognate
492 antigens, thereby explaining the involvement of migratory cDC2s in both Th2 and Tfh responses⁸⁸.

493
494 The initial cellular source of IL-4 in draining LNs has not been clearly defined, yet recently stimulated T
495 cells can produce IL-4 in a TCR-dependent manner *in vitro*^{19,20}. Mice deficient in IL-4R α also retain the
496 capacity to secrete IL-4, suggesting that T cells can produce IL-4 without a requirement for prior IL-4
497 sensing⁸⁹. Consistent with this, IL-4 secretion by T cells can be achieved by the activation of BATF/IRF4/Jun
498 complexes downstream of TCR engagement and costimulation in a Gata3-independent manner⁶⁷⁻⁷⁵.
499 Indeed, we observe robust expression of IRF4 and BATF in activated T cells within ear draining auricular
500 LNs, suggesting these transcription factors may be sufficient to induce initial IL-4 production by
501 responding T cells within macro-clusters which can then be further amplified by canonical IL-4/IL-4R α
502 driven Gata3 expression. While our studies do not examine other potential sources of IL-4 in LNs, the
503 majority of activated OT-II T cells express pSTAT6, indicative of more widespread cytokine sensing after
504 papain administration⁹⁰. Our findings do suggest that T cells within the macro-clusters experience more
505 extensive cytokine signaling than those outside the clusters, and this further enhances Th2 differentiation
506 within local microenvironments. Supporting this are past observations that both IL-2 and IL-4 are secreted
507 by T cells in a broadcasted, non-polarized fashion^{91,92}, as well as our results demonstrating that late CD28
508 blockade, which disrupts macro-clustering, results in diminished STAT phosphorylation.

509

510 Of note, our data also suggest that during papain exposure, antigen-bearing migratory cDC2s have low
511 levels of pMHC complexes on the cell surface, accompanied by high amounts of costimulatory molecules
512 and integrin ligands. Mechanisms of how type-II inflammation impacts antigen processing and
513 presentation, as well as whether it extends to other type-II settings remains to be determined, but could
514 be driven in part by modulating the cytoskeletal properties of cDCs⁹³. Together with TCR engagement,
515 costimulation enhances LFA-1 integrin activation, which enables prolonged T cell – cDC interactions, as
516 well as reduces the threshold of TCR signaling required for T cell activation, overall being consistent with
517 our findings that low levels of pMHC-II can still lead to robust T cell responses⁷⁷. Additional integrin-
518 mediated homotypic interactions among activated T cells may also take place, albeit likely not via ICAM-
519 1 / LFA-1 interactions. Of note, a recent study has demonstrated a role for the integrin $\alpha V\beta 3$, for Th2
520 differentiation *in vitro*, and this integrin has also been previously linked with migratory behavior of Th2
521 cells in inflamed tissues^{94,95}.

522
523 A key unexpected finding in our work was that not all types of skin generated equivalent Th2 responses
524 in the draining LNs. Our studies primarily focused on the ear vs footpad draining LNs, but additional
525 variation across the skin is likely. A major unanswered question remains as to why cDCs within different
526 skin sites are non-equivalently activated after exposure to the same agonist and whether this extends to
527 other barrier tissues in mice and humans. Homeostatic tissue signals like IL-13 and IL-18 can impart cDCs
528 and ILC2s with a tissue-specific identity, potentially reflecting intrinsic pre-programming of cDCs and other
529 cells based on skin type residence⁹⁶⁻⁹⁸. In addition, differences could reflect divergent cDC experiences at
530 the site of immunization. Many cytokines, including alarmins, are released from epithelial and stromal
531 cells during type-II inflammation and barrier disruption events, and whether these cytokines are
532 equivalently released between skin sites requires further study. There could be many additional tissue
533 specific adaptations, such as neuronal composition, mast cell differences, or divergent microbiomes which
534 direct dermal cDC2 maturation and activation⁹⁹⁻¹⁰². Epidermal barrier thicknesses and other structural
535 differences between skin sites could also contribute¹⁰³. Therefore, skin should not be thought of as a single
536 barrier tissue, but unique compartments which may respond differently to environmental triggers. A
537 possible evolutionarily benefit of reduced Th2 responses after footpad allergen administration could
538 reflect the need for dampened inflammation in tissues with constant mechanical stress, environmental
539 exposure, and likely damage, while still retaining the ability to induce robust Th1 responses to microbial
540 challenges. Finally, a common feature of Th2 allergic responses is atopic march development, in which
541 initial skin sensitization leads to downstream pathology across peripheral organs. It will thus be important

542 to understand how different regions of the skin, the largest barrier tissue in the body, respond to allergen
543 exposure and drive disease development.

544




Figure 1. Generation of Th2 microenvironments in draining LNs.

545 **Figure Legends**

546 Figure 1. Generation of Th2 microenvironments in draining LNs. A-H) Naïve Ly5.2 4get.OT-II T cells were
547 transferred to Ly5.1 mice and injected with the indicated adjuvants plus OVA in the ear pinnae. Mice were
548 treated intraperitoneally with α -CD62L blocking antibody 6 hours post immunization and dLNs were
549 harvested and assessed by histo-cytometry at 48 hours. A-B) Representative images depicting OT-II
550 macro-clustering at the T-B border in Papain OVA immunized dLNs with B) macro-clustered and non-
551 clustered regions highlighted in insets with the indicated markers shown. C) Representative images
552 depicting OT-II responses in dLNs after CpG OVA immunization. D) Histo-cytometry analyses of OT-II
553 localization with respect to the T-B border and the ratio of macro-clustered vs. total OT-II are shown. E-H)
554 dLN tissue sections were analyzed for association of Th2 cells with myeloid cells. E) Representative image
555 demonstrating Th2 macro-clusters and different myeloid cell markers. F-H) Spatial distribution analysis of
556 myeloid cells and activated (IRF4⁺Ki67⁺) T cell subsets was performed using CytoMAP. F) 50 μ m raster scan
557 neighborhoods of a representative dLN were plotted on a X,Y positional plot and color-coded using
558 neighborhood clustering, as shown in panel G. G) Heatmap demonstrating the cellular composition for
559 the different neighborhood clusters (color code depicted at the top). Th2 regions (dark red) enriched with
560 CD301b⁺ DCs are highlighted (arrowhead). H) Cell-cell spatial correlation of the indicated T cell subsets
561 and myeloid cell populations. I) Naïve Ly5.1 OT-II T cells were transferred into CD11c-Cre⁺ IRF4^{fl/fl} or
562 CD11c-Cre^{neg} IRF4^{fl/fl} Ly5.2 mice and immunized with papain and OVA in the ear pinnae, treated with α -
563 CD62L blocking antibody at 6 hours, and dLNs were harvested and assessed by flow cytometry at 48 hours.
564 I) CD44⁺ OT-II cell number is shown with representative histograms of Gata3 gMFI of CD44⁺ OT-II cells,
565 IRF4 gMFI, and BCL6 gMFI on Gata3^{neg} CD44⁺ OT-II cells. BF = B cell follicles; TZ = T cell zone. Dashed lines
566 represent T-B border. Figures A-D are representative of 5 independent experiments. Figures E-I are
567 representative of 3 independent experiments.

568

569








Figure S1. Cellular composition of Th2 microenvironments after papain immunization or *N.b.* infection.

570 Figure S1. Cellular composition of Th2 microenvironments after papain immunization or *N.b.* infection.
571 A) 4get-GFP mice were immunized in the ear pinnae with papain and auricular dLNs or non-draining naïve
572 LNs were harvested for confocal microscopy 3 days later. Representative images and zoom ins are shown
573 with the indicated markers. B) 4get-GFP mice were inoculated subcutaneously at the tail base with 500
574 *N.b.* L3 larvae and the draining mesenteric LN (MLN) or MLN from naïve mice were harvested 6 days later
575 for confocal microscopy. Representative image and zoom in depicting Th2 macro-clustering in the MLN
576 with the indicated markers is shown. C) Naïve Ly5.2 4get.OT-II T cells were transferred to Ly5.1 mice and
577 injected with papain OVA in the ear pinnae, treated with α -CD62L blocking antibody at 6 hours, and
578 harvested for flow cytometry 48 hours later. Representative gating for T follicular helper (Tfh) and T
579 effector (Teff) OT-II cells is shown with the indicated markers. D) B6 mice were immunized with papain in
580 the ear pinnae and auricular dLNs were harvested 3 days later for flow cytometry. Representative gating
581 for endogenous T cell activation is shown with Gata3, BCL6, and CD25 identifying Tfh and Teff T cells. E)
582 KN2^{+/-} mice were immunized with papain in the ear pinnae and auricular dLNs or naïve lymph nodes (nLN)
583 were harvested 4 days later for flow cytometry. Representative plot and quantification of huCD2 and
584 Gata3 expression is shown. F) CD11c-Cre⁺ IRF4^{fl/fl} or CD11c-Cre^{neg} IRF4^{fl/fl} were immunized with papain in
585 the ear pinnae and dLNs were harvested 2 days later for flow cytometry. Quantification of the indicated
586 myeloid cell subsets is shown. BF = B cell follicles; TZ = T cell zone. Dashed lines represent T-B border. A,
587 C-D are representative of 5 independent experiments. B, E-F are representative of 2-3 independent
588 experiments.
589
590




Figure 2. Th2 macro-clustering and differentiation is site-specific.

591 Figure 2. Th2 macro-clustering and differentiation is site-specific. A-E) Naïve Ly5.2 4get.OT-II cells were
592 transferred to Ly5.1 mice and injected with the indicated adjuvant plus OVA in the ear pinnae or front
593 footpad, treated intraperitoneally with α -CD62L 6 hours post immunization, and dLNs were harvested and
594 assessed by histo-cytometry and flow cytometry at 48 hours. Representative images depicting OT-II
595 macro-clustering and expression of the indicated markers in A) auricular vs B) brachial dLNs. C) Histo-
596 cytometry analysis of the percent activated OT-II co-expressing 4get-GFP and Gata3, OT-II localization,
597 and the ratio of macro-clustered vs. total OT-II in the indicated LNs. D-E) Representative plots and
598 quantification of CD44⁺ OT-II cell number, frequency of 4get-GFP⁺ and CXCR3⁺ cells, and Gata3 and Tbet
599 gMFI of CD44⁺ OT-II cells. F-G) 0.5x10⁶ naïve Ly5.2 4get.OT-II cells were transferred to Ly5.1 mice then
600 injected with papain OVA in the ear pinnae or front footpad. 6 days later, cells were labeled intravenously,
601 and dLNs, spleen, and lung were harvested and assessed by flow cytometry. Representative plots and
602 quantification of frequency of 4get-GFP⁺ and Gata3 gMFI of I.V.^{neg} CD44⁺ OT-II cells and total CD44⁺ OT-II
603 cell number are shown. Au = auricular; Br = brachial; IV = intravenous. Dashed lines represent T-B border.
604 A-E are representative of 5 independent experiments. F-G are representative of 2 independent
605 experiments.
606
607




Figure S2. Site-specific Th2 responses are maintained across mouse strains and adjuvants.

608 Figure S2. Site-specific Th2 responses are maintained across mouse strains and adjuvants. A) 0.5×10^6 naïve
609 Ly5.2 4get.OT-II cells were transferred to Ly5.1 mice and injected with papain OVA in the ear pinnae or
610 front footpad and dLNs, spleen, and lung were harvested and assessed by flow cytometry 6 days later.
611 BCL6 gMFI of CD44⁺ OT-II cells and frequency of CXCR5⁺PD-1⁺ CD44⁺ OT-II cells are shown. B) KN2^{+/-} mice
612 were immunized with papain in the ear pinnae or front footpad and dLNs were assessed by flow cytometry
613 2 days later. Representative plot and frequency of KN2⁺Gata3⁺ and KN2 gMFI of CD44⁺Ki67⁺ CD4 cells are
614 shown. C) B6 or Balb/c mice were immunized in the ear pinnae and front footpad with papain and dLNs
615 were harvested at day 3 for flow cytometry. Activated CD44⁺Ki67⁺ T cell number, and Gata3 and IRF4 gMFI
616 of CD44⁺Ki67⁺ T cells are shown. D) B6 mice were immunized in the ear pinnae and front footpad with
617 papain or Alum OVA and dLNs were harvested at day 3 for flow cytometry. Activated CD44⁺Ki67⁺ T cell
618 number, and Gata3 and IRF4 gMFI of CD44⁺Ki67⁺ T cells are shown. E) Naïve Ly5.2 4get.OT-II cells were
619 transferred to Ly5.1 mice, injected with papain OVA or Alum OVA in the ear pinnae or front footpad,
620 treated intraperitoneally with α -CD62L 6 hours post immunization and dLNs were harvested and assessed
621 by flow cytometry at 48 hours. Representative plots, CD44⁺ OT-II cell number, expression of 4get-GFP of
622 CD44⁺ OT-II cells, and Gata3 and IRF4 gMFI of CD44⁺ OT-II cells are shown. F-G) Naïve Ly5.2 4get.OT-II cells
623 were transferred to Ly5.1 mice, and injected with papain OVA in the ear pinnae, front footpad, hind
624 footpad, dorsal flank skin, or tail base. Mice were treated intraperitoneally with α -CD62L 6 hours post
625 immunization and dLNs were harvested and assessed by flow cytometry at 48 hours. Representative plots,
626 CD44⁺ OT-II cell number, frequency of 4get-GFP⁺ cells and Gata3 gMFI of CD44⁺ OT-II cells are shown. H)
627 DBP was topically applied (painted) onto the ear or front footpad skin of mice. dLNs were harvested for
628 flow cytometry 48 hours later. Activated CD44⁺Ki67⁺ T cell number, and Gata3 and IRF4 gMFI of
629 CD44⁺Ki67⁺ T cells are shown. A-G are representative of 2-3 independent experiments. H is representative
630 of 4 independent experiments.

631

632




Figure 3. Costimulation is enhanced on DCs from auricular LNs.

633 Figure 3. Costimulation is enhanced on DCs from auricular LNs. A-H) B6 mice were immunized in the ear
634 pinnae and front footpad with papain plus E α GFP and the corresponding dLNs were harvested 48 hours
635 later. A) Representative plots showing total E α GFP expression within live cells. B) Quantification of the
636 number of E α GFP⁺ migratory DCs and E α GFP⁺ gMFI of migratory DCs. Symbol shapes represent
637 independent experiments (three total). C) Quantification of total E α GFP⁺ cells for the indicated DC
638 subsets. D-F) E α GFP⁺ DC populations were sorted from dLNs on day 2 for bulk RNA sequencing. DCs were
639 sorted on Live, CD64^{neg}, Lineage^{neg} (CD3, CD19, NK1.1), E α GFP⁺, MHC-II^{Hi} CD11c^{Int}, XCR1^{neg}, EpCAM^{neg}, then
640 sorted into CD11b⁺ CD301b⁺, CD11b⁺ CD301b^{neg}, and CD11b^{neg} CD301b^{neg} populations. The same gates
641 were used for E α GFP^{neg} DCs in naïve LNs. D) PCA plot of all samples (left) and papain immunized DC
642 populations (right). E) Heatmap of the top 100 DEGs between antigen-bearing migratory DCs from
643 auricular vs. brachial dLNs (FDR<0.05, 2x fold change expression). F) Volcano plot of DEGs between
644 antigen-bearing migratory DCs from auricular and brachial dLNs. Red indicates a FDR<0.05. Genes with a
645 log fold change greater than 2 are shown. G-H) E α GFP⁺ migratory DCs were assessed for surface CD80 and
646 CD86 expression by flow cytometry. G) Representative flow plots for CD301b⁺ cDC2s and H) quantification
647 for three indicated DC subsets are shown. Au = auricular; Br = brachial. A-C, and G-H are representative of
648 3 independent experiments. D-F are representative of 1 independent RNA sequencing experiment with
649 n=3 per group.
650
651




Figure S3. Transcriptional signatures of naïve and activated cDC2s.

652 Figure S3. Transcriptional signatures of naïve and activated cDC2s. A-D) B6 mice were immunized in the
653 ear pinnae or front footpad with papain or CpG and E α GFP as indicated and harvested 48 hours later. A)
654 Total number of E α GFP^{neg} cells for the indicated DC subsets. B) Frequency of E α GFP⁺ cells for the indicated
655 cell subsets. C-D) Representative flow plots and quantification showing E α GFP and YAc expression on
656 migratory DCs after immunization with the indicated adjuvant. Symbol shape represents individual
657 experiments (three total). E-F) E α GFP⁺ DC populations were sorted from dLNs on day 2 for bulk RNA
658 sequencing. E) Heatmap of all DEGs with a FDR<0.05 and greater than 2x fold change between naïve and
659 papain immunized DCs from auricular and brachial LNs is shown. F) Volcano plot of DEGs between papain
660 immunized and naïve DCs from auricular and brachial dLNs. Red indicates a FDR<0.05. Genes with a log
661 fold change greater than 2 are shown. G) Migratory DCs were assessed for surface PD-L1 and PD-L2
662 expression by flow cytometry. Quantification of the frequency of PD-L1 and PD-L2 for the indicated DC
663 subsets is shown. H) GO term enrichment analysis based on all DEGs in E α GFP⁺ CD11b⁺ DC populations
664 between auricular and brachial dLNs. Au = auricular; Br = brachial. A-D, G are representative of 3
665 independent experiments. E-F and H are representative of 1 independent RNA sequencing experiment
666 with n=3 per group.

667

668




Figure 4. Non-equivalent expression of costimulatory molecules by migratory cDC2s drives divergent T cell activation states.

669 Figure 4. Non-equivalent expression of costimulatory molecules by migratory cDC2s drives divergent T cell
670 activation states. A-D) Naïve Ly5.2 4get.OT-II cells were transferred to Ly5.1 mice, injected with papain
671 OVA or CpG OVA in the ear pinnae or front footpad, treated intraperitoneally with α -CD62L 6 hours post
672 immunization, and dLNs were harvested and assessed by histo-cytometry or flow cytometry at 48 hours.
673 A-C) Expression of IRF4 and BATF on activated CD44⁺ OT-II cells and correlation plots with Gata3 gMFI and
674 frequency of 4get-GFP⁺ cells across different dLNs is shown. D) Representative histo-cytometry plots and
675 quantification of pS6 and Gata3 expression in activated Ki67⁺IRF4⁺ OT-II T cells. E) Naïve Ly5.2 4get.OT-II
676 cells were transferred to Ly5.1 mice and injected with a fixed concentration of papain and increasing
677 concentrations of OVA in the ear pinnae or front footpad. Mice were treated intraperitoneally with α -
678 CD62L 6 hours post immunization and dLNs were harvested and assessed by flow cytometry at 48 hours.
679 CD44⁺ OT-II cell number, frequency of 4get-GFP⁺ cells, and Gata3, IRF4, and Tbet gMFI expression on CD44⁺
680 OT-II cells are shown. Data are representative of at least 3 independent experiments.
681
682

683 Figure 5. Site-specific T cell responses are mediated through non-equivalent expression of costimulatory
684 molecules by migratory cDCs. A-D) Naïve Ly5.2 4get.OT-II cells were transferred to Ly5.1 mice and injected
685 with papain OVA in the ear pinnae or front footpad. Mice were treated intraperitoneally with α -CD62L 6
686 hours post immunization, treated intraperitoneally with α -CD28 blocking antibody or IgG isotype control
687 24 hours post immunization, and dLNs were harvested and assessed by histo-cytometry or flow cytometry
688 at 48 hours. A) Representative flow plots and quantification of CD44⁺ OT-II cell number, 4get-GFP⁺
689 frequency and Gata3 and IRF4 gMFI of CD44⁺ OT-II cells after α -CD28 or isotype control treatment. B)
690 Representative images depicting OT-II responses in auricular dLN treated with isotype control (top) or α -
691 CD28 blocking antibody (bottom). Dashed lines represent the T-B border. C-D) Histo-cytometry analysis
692 of 4get-GFP and Gata3 expression, OT-II localization, and frequency of macro-clustered OT-II cells. E-G)
693 Naïve OT-II cells were cultured *in vitro* with the indicated concentrations of α -CD3 and α -CD28. α -IFN γ
694 was added to cultures in some conditions (dashed lines). Cells were harvested 48 hours later and assessed
695 for expression of Gata3 and IRF4 by flow cytometry. Representative plots of IRF4 and Gata3 expression
696 are shown with quantification. A-D are representative of at least 2 independent experiments. E-G are
697 representative of 4 independent experiments.
698
699

700 Figure S5. Late CD28 blockade has a minimal effect on Th1 differentiation. A) Naïve Ly5.2 4get.OT-II cells
701 were transferred to Ly5.1 mice and injected with CpG OVA in the ear pinnae or front footpad. Mice were
702 treated intraperitoneally with α -CD62L 6 hours post immunization, treated intraperitoneally with α -CD28
703 blocking antibody or IgG isotype control 24 hours post immunization, and dLNs were harvested and
704 assessed by flow cytometry at 48 hours. Quantification of CD44⁺ OT-II cell number, frequency of CXCR3⁺
705 cells, and Tbet gMFI on CD44⁺ OT-II cells are shown. B) Naïve OT-II cells were cultured *in vitro* with the
706 indicated concentrations of α -CD3 and α -CD28. IL-4 and α -IFN γ were added to the culture in some
707 conditions (dashed lines). Cells were harvested for flow cytometry 48 hours later and assessed for
708 expression of Gata3 and IRF4. Representative plots of IRF4 and Gata3 expression are shown with
709 quantification. A is representative of 2 independent experiments. B is representative of 4 independent
710 experiments.

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726




Figure 6. Th2 macro-clustering and differentiation is driven by prolonged ICAM1-mediated DC-T cell contacts.

727 Figure 6. Th2 macro-clustering and differentiation is driven by prolonged ICAM-1 mediated DC-T cell
728 contacts. A) B6 mice were immunized in the ear pinnae and front footpad with papain or CpG plus E α GFP
729 and harvested for flow cytometry 48 hours later. Expression of ICAM-1 on E α GFP⁺ and E α GFP^{neg} or naïve
730 migratory DCs in the indicated LNs is shown. B-F) Naïve Ly5.2 4get.OT-II cells were transferred to Ly5.1
731 mice and injected with papain OVA in the ear pinnae or front footpad. Mice were treated intraperitoneally
732 with α -CD62L 6 hours post immunization, treated intraperitoneally with α -LFA1 blocking antibody or IgG
733 isotype control 24 hours post immunization, and dLNs were harvested and assessed by flow cytometry
734 and imaging at 48 hours. B) Representative flow plots showing 4get-GFP and CXCR3 expression on CD44⁺
735 OT-II cells. C) Quantification of the number of CD44⁺ OT-II cells, frequency of 4get-GFP⁺ cells, and Gata3
736 and IRF4 gMFI of CD44⁺ OT-II cells after α -LFA1 or isotype control treatment. D) Representative
737 microscopy images depicting OT-II responses in auricular dLN treated with isotype control (top) or α -LFA1
738 blocking antibody (bottom). Dashed lines represent T-B border. E-F) Histo-cytometry analysis of 4get-GFP
739 and Gata3 expression, OT-II localization, and frequency of macro-clustered OT-II cells in auricular LNs with
740 the indicated treatments. A, D-F are representative of 2 independent experiments. B-C are representative
741 of 4 independent experiments.
742
743

744 Figure S6. ICAM-1 expression on T cells is dispensable for Th2 differentiation. A-B) Naïve Ly5.2 4get.OT-II
745 cells were transferred to Ly5.1 mice and injected with CpG OVA in the ear pinnae or front footpad. Mice
746 were treated intraperitoneally with α -CD62L 6 hours post immunization, treated intraperitoneally with α -
747 LFA1 blocking antibody or IgG isotype control 24 hours post immunization, and dLNs were harvested and
748 assessed by flow cytometry at 48 hours. A) Representative plots showing 4get-GFP and CXCR3 expression
749 on CD44⁺ OT-II cells. B) Quantification of CD44⁺ OT-II cell number, frequency of CXCR3⁺ cells, and Tbet
750 gMFI on CD44⁺ OT-II is shown. C-D) Naïve ICAM-1.KO or ICAM-1.WT OT-II cells were transferred to CD45.1⁺
751 B6 recipients and injected with papain OVA in the ear pinnae or front footpad, treated intraperitoneally
752 with α -CD62L 6 hours post immunization, and dLNs were harvested and assessed by flow cytometry at 48
753 hours. C) Frequency of ICAM-1⁺ OT-II cells from ICAM-1.WT and ICAM-1.KO mice. D) Quantification of the
754 number of CD44⁺ OT-II cells, and Gata3 and IRF4 gMFI of CD44⁺ OT-II cells. WT = wild type; KO = knockout.
755 Data are representative of 2 independent experiments.
756
757




Figure 7. Increased costimulation in auricular draining LNs promotes increased cytokine signaling and Th2 differentiation.

758 Figure 7. Increased costimulation in auricular draining LNs promotes increased cytokine signaling and Th2
759 differentiation. A-D) Naïve Ly5.1 OT-II T cells were transferred to B6 mice and injected with papain OVA
760 in the ear pinnae or front footpad. Mice were treated intraperitoneally with α -CD62L blocking antibody 6
761 hours post immunization and dLNs were harvested and assessed by flow cytometry at 48 hours. A)
762 Representative flow plots of Gata3 and CD25 expression on CD44⁺ OT-II cells in auricular dLNs. B)
763 Representative histograms and quantification of pSTAT5 and pSTAT6 staining for the indicated cell subsets
764 within the same sample. C) Representative histograms and quantification of pSTAT5 and pSTAT6
765 expression in auricular and brachial LNs and D) pSTAT5 and pSTAT6 correlation with Gata3 gMFI on CD44⁺
766 OT-II cells is shown. E-F) Naïve Ly5.1 OT-II cells were transferred to B6 mice and injected with papain OVA
767 in the ear pinnae or front footpad. Mice were treated intraperitoneally with α -CD62L 6 hours post
768 immunization, treated intraperitoneally with α -CD28 blocking antibody, α -IL-2 blocking antibody, or IgG
769 isotype control 24 hours post immunization, and dLNs were harvested and assessed by flow cytometry at
770 48 hours. Quantification of frequency of pSTAT5⁺ and pSTAT6⁺ cells, gMFI of pSTAT5 and pSTAT6, and
771 Gata3 expression on CD44⁺ OT-II cells are shown. Data are representative of at least 2 independent
772 experiments.

773

774

775




Figure S7. Proposed model for initiation of Th2 differentiation in skin draining LNs.

776 Figure S7. Proposed model for initiation of Th2 differentiation in skin draining LNs. Papain immunization
777 of the skin elicits the maturation and migration of migratory antigen-bearing cDC2 to draining LNs where
778 they induce Th2 responses within dedicated microenvironments localized at the T-B border. Th2
779 differentiation is driven by prolonged T – DC contacts leading to T cell activation through low levels of
780 pMHC and high levels of costimulatory molecules on cDC2s thus driving integrin-mediated macro-
781 clustering, efficient cytokine exchange, and localized Th2 differentiation. Certain skin sites, such as the
782 paw, induce reduced expression of costimulatory molecules on cDC2s which leads to reduced Th2
783 responses within corresponding draining LNs.

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808 **Materials & Methods**

809 **Mice**

810 C57BL/6J, BALB/cJ, B6.Cg-Tg(Itgax-cre)1-1Reiz/J (CD11c-Cre), B6.129S1-Irf4^{tm1Rdf}/J (IRF4^{fl/fl}), and B6.129S4-
811 *Icam1*^{tm1cgr}/J (ICAM-1.KO) were obtained from Jackson Laboratory. B6.SJL-*Ptprc^aPepec^b*/BoyCrI (CD45.1)
812 mouse strain was obtained from Charles River Laboratory. CD45.1⁺ B6.Cg-Tg(TcraTcrb)425Cbn/J (OT-II)
813 mice were obtained from a donating investigator (P.J. Fink, University of Washington) and crossed with
814 CD45.2⁺ C57BL/6J mice to generate CD45.1⁺ OT-II and CD45.1⁺CD45.2⁺ OT-II lines that were used
815 interchangeably based on recipient congenic status. The KN2 and 4get-GFP mouse strains on a B6
816 background were obtained from a donating investigator (M. Pepper, University of Washington). 4get-GFP
817 and ICAM-1.KO mice were crossed to OT-II to generate 4get-GFP OT-II and ICAM-1.KO OT-II lines
818 respectively.

819

820 Six- to twelve-week-old male and female mice were kept in specific pathogen-free (SPF) conditions at an
821 Association for Assessment and Accreditation of Laboratory Animal Care-accredited facility at the
822 University of Washington, South Lake Union campus. All procedures were approved by the University of
823 Washington Institutional Animal Care and Use Committee.

824

825 **Adoptive transfers**

826 For adoptive transfers, naïve CD45.1⁺ OT-II, CD45.1⁺CD45.2⁺ OT-II, or CD45.2⁺ 4get-GFP OT-II T cells were
827 isolated from LNs and spleens using the naïve CD4⁺ T cell isolation kit (Miltenyi Biotec). The average purity
828 of OT-II cells was approximately 75-80% for all experiments. 1x10⁶ (unless otherwise noted) naïve OT-II
829 cells were transferred into hosts intravenously via retro-orbital injection 1-3 days prior to immunization.

830

831 **Immunizations and blocking antibodies**

832 The following adjuvants and amounts per immunization site were used: 20µg of CpG ODN 1668
833 (AdipoGen), Alhydrogel (“Alum”) (Invivogen) diluted 1:2 with PBS, Dibutyl pthalate (“DBP”) (Sigma Aldrich)
834 diluted 1:1 with 100% Acetone, 50µg Papain (Sigma-Aldrich), and 10µg Endotoxin-free Ovalbumin (“OVA”)
835 (Invivogen). In some studies, the dose of OVA given ranged from 0.1-100µg per injection. For antigen
836 presentation studies, 10µg of LPS-free EαGFP (gift from M. K. Jenkins, University of Minnesota) plus 50µg
837 of papain were injected intradermally in the ear pinnae or the forepaw. Adjuvants were mixed with PBS
838 in a 20µl total volume per immunization site and injected in the hind or front footpads, subcutaneously in
839 the flank skin, at the tail base, or intradermally in the ear pinnae (to target the popliteal, Brachial, Inguinal,

840 and Auricular dLNs, respectively) as indicated. For some studies, DBP was “painted” onto ear or footpad
841 skin by pipetting 20µl volume slowly, allowing drying between drops with the mouse under anesthesia
842 until liquid was completely dried.

843
844 For *in vivo* antibody blocking studies, 100µg of anti-CD62L (clone Mel-14, BioXcell) was injected
845 intraperitoneally 6 hours post immunization. In some studies 100µg anti-LFA-1α (clone M17/4, BioXcell),
846 100µg rat IgG2a isotype control (BioXcell), 100µg anti-CD28 (clone 37.51, BioXcell), 100µg polyclonal
847 Syrian hamster IgG (BioXcell), or 100µg anti-IL-2 (clone JES6-1A12, BioXcell) was injected intraperitoneally
848 24 hours post immunization.

849
850 **Confocal microscopy**

851 For confocal imaging, PFA-fixed and sectioned LN tissues were imaged as previously described using a
852 Leica SP8 microscope⁵⁸. Briefly, isolated LN tissues were fixed using BD Cytotfix (BD Biosciences) diluted
853 1:3 in PBS for 24 hours at 4°C then dehydrated with 30% sucrose solution for 24-48 hours at 4°C. LNs were
854 then embedded in OCT compound (Tissue-Tek) and stored at -20°C. LNs were section on a Thermo
855 Scientific Micron HM550 cryostat into 20µm sections and stained as previously described⁵⁸. A Leica SP8
856 tiling confocal microscope equipped with a 40x 1.3NA oil objective was used for image acquisition. All raw
857 imaging data was processed and analyzed using Imaris (Bitplane).

858
859 **Histo-cytometry and CytoMAP**

860 Histo-cytometry analysis was performed as previously described^{38,58}. Briefly, multiparameter confocal
861 images were corrected for fluorophore spillover using the built-in Leica Channel Dye Separation module.
862 Single stained controls were acquired using UltraComp eBeads (Invitrogen) that were incubated with
863 fluorescently conjugated antibodies, mounted on slides with Fluormount-G slide mounting media
864 (ThermoFisher), and imaged. All images were visualized and analyzed using Imaris (Bitplane). For analysis
865 of myeloid cells, a combinatorial myeloid channel was created by adding normalized signals for CD11c,
866 MHC-II, CD207, CD301b, and Sirpα using the Imaris XT channel arithmetic module, and this sum myeloid
867 channel was used for myeloid isosurface object creation. For T cells, a combined activated T cell channel
868 was created by adding normalized signals for Ki67 and IRF4; T cell isosurface objects were next created on
869 this channel and then further gated on the congenic CD45.1 or CD45.2 signal. In all analyses, object
870 statistics were exported to FlowJo software (FlowJo, LLC) for gating and phenotypic characterization. T-B
871 border regions were manually created using B220 or MHC-II (B cell follicles) and CD3 (T cell zone) staining

872 and represented as a surface. T-B border localization was calculated as the frequency of OT-II cells within
873 the T-B border surface region. Clustering analysis was performed by creating isosurfaces on CD45.1
874 congenic signal without cell splitting. Surfaces were then filtered by volume and surfaces exceeding
875 $1400\mu\text{m}^3$ were added and presented as a ratio of macro-clustered surface volume (greater than $1400\mu\text{m}^3$)
876 to total OT-II surface volume. Spatial correlation analysis was performed in CytoMAP⁴². In brief, the
877 position of all myeloid and T cell objects within LNs was used for virtual raster scanning with 50- μm radius
878 neighborhoods. The Pearson correlation coefficient was calculated for the number of cells of the different
879 cell types within these neighborhoods. Raster-scanned neighborhoods were also used for clustering based
880 on cell type abundance to identify distinct region types, and these regions were used for heatmap and
881 positional visualization of regions in dLNs.

882

883 **Cell isolation and flow cytometry**

884 For myeloid cell analysis, LN tissues were mechanically disrupted and subject to digestion in PBS with 10%
885 fetal bovine serum (FBS) with DNase I ($100\mu\text{g}/\text{mL}$; Sigma), Dispase II ($800\mu\text{g}/\text{mL}$; Sigma), and Collagenase
886 P ($200\mu\text{g}/\text{mL}$; Sigma) at 37°C shaking at 150rpm for 30 minutes with periodic manual disruption. Flow
887 cytometric studies of T cells in lymph nodes did not use enzymatic digestion. In some studies, mice were
888 injected intravenously with $1\mu\text{g}$ of anti-Thy1.2-BUV395 (clone 30-H12; BD Biosciences) ~5 minutes prior
889 to sacrifice. Lung tissue was digested in complete RPMI with Liberase ($70\mu\text{g}/\text{mL}$; Roche) and
890 Aminoguanidine (10mM ; Sigma) and tissue was dissociated on the gentleMACS Dissociator (Miltenyi
891 Biotec) as previously described²². Cell staining was conducted in the presence of Fc Block (2.4G2, Tonbo
892 Biosciences) at 4°C for 30 minutes for all surface markers except CXCR5-biotin which was stained at room
893 temperature for 45 minutes. Intracellular staining was performed for 45 minutes at 4°C after fixation with
894 the FOXP3 Fix/perm kit (Invitrogen). In some studies, an addition permeabilization step was performed in
895 90% ice-cold methanol prior to intracellular staining. Data were acquired on an Aurora flow cytometer
896 (Cytex) and analyzed using FlowJo software (BD Biosciences).

897

898 **CD4⁺ T cell isolation and culture**

899 For *in vitro* T cell stimulation experiments, naïve CD4⁺ T cells were isolated from LNs and spleens using the
900 naïve CD4⁺ T cell isolation kit (Miltenyi Biotec) into complete RPMI media. 400,000 cells were then plated
901 on pre-treated plates coated with the indicated concentrations of anti-CD3 ϵ (145-2C11, Thermo Scientific)
902 and anti-CD28 (37.51, Thermo Scientific) under Th0, +anti-IFN γ $10\mu\text{g}/\text{mL}$; (XMG1.2, Biolegend), or Th2

903 (anti-IFN γ 10 μ g/mL (XMG1.2, Biolegend), rIL-4 50ng/mL (Peprotech)) conditions. Cells were cultured for
904 48 hours at 37°C and 5% CO $_2$ before fixation and flow cytometric analysis.

905

906 **RNA sequencing**

907 Single cell suspensions from tissues were prepared as described above for myeloid cells. Cells were sorted
908 from pooled dLNs from 3 individual mice for each group. 500 of each cDC2 cell type was sorted on an Aria
909 III (BD Biosciences) directly into reaction buffer from the SMART-Seq v4 Ultra Low Input RNA Kit for
910 Sequencing (Takara), and reverse transcription was performed followed by PCR amplification to generate
911 full length amplified cDNA. Sequencing libraries were constructed using the NexteraXT DNA sample
912 preparation kit with unique dual indexes (Illumina) to generate Illumina-compatible barcoded
913 libraries. Libraries were pooled and quantified using a Qubit Fluorometer (Life Technologies). Sequencing
914 of pooled libraries was carried out on a NextSeq 2000 sequencer (Illumina) with paired-end 59-base reads,
915 using NextSeq P2 sequencing kits (Illumina) with a target depth of 5 million reads per sample. Base calls
916 were processed to FASTQs on BaseSpace (Illumina), and a base call quality-trimming step was applied to
917 remove low-confidence base calls from the ends of reads. The FASTQs were aligned to the GRCm38
918 mouse reference genome, using STAR v.2.4.2a and gene counts were generated using htseq-count. QC
919 and metrics analysis was performed using the Picard family of tools (v1.134). Further downstream analysis
920 was performed using publicly available RNAseq toolkits. The Degust toolkit¹⁰⁴ (v4.1.1) with integrated
921 Voom/Limma R package was used for differentially expressed gene analysis and generation of volcano
922 plots. Only genes with count per million (CPM) ≥ 10 were analyzed further. Genes were filtered based on
923 a false discovery rate cutoff ≤ 0.05 and a minimum expression fold change ≥ 2 . DEGs were input into the
924 WebGestalt gene set analysis toolkit¹⁰⁵ to identify Biological Processes Gene Ontology (GO) terms and
925 generate the associated graphs. Heatmap data tables were generated by inputting DEG data into the
926 BIOMEX toolkit¹⁰⁶. PCA plots were generated via the DEBrowser toolkit¹⁰⁷ (v1.26.3), where only genes with
927 CPM ≥ 10 were analyzed.

928

929 **Antibodies & staining reagents**

930 Antibodies used for staining sections for confocal imaging or isolated cells for flow cytometry include:
931 CD64 (clone X54-57.1; BioLegend), B220 (clone RA3-6B2; Biolegend), SIRP α (clone P84; BD Biosciences),
932 CD11c (clone N418; BD Biosciences), CD11b (clone M1/70; Biolegend), MHCII (clone M5/114.15.2;
933 BioLegend), IRF4 (clone IRF4.3E4; BioLegend), CD45.1 (clone A20; BioLegend), Ki67 (clone B56; BD
934 Biosciences), Y-Ae (clone eBioY-Ae; ThermoFisher Scientific), Thy1.2 (clone 30-H12; BD Biosciences), CD3

935 (clone 17A2; BD Biosciences), Tbet (clone 4B10; BioLegend), NK1.1 (clone PK136; BioLegend), CD19 (clone
936 6D5; BioLegend), CD44 (clone IM7; BioLegend), XCR1 (clone ZET; BioLegend), GATA3 (clone L50-823; BD
937 Biosciences), CXCR3 (clone CXCR3-173; BioLegend), CXCR5 (clone 2G8; BD Biosciences), pS6 (clone 2F9;
938 Cell Signaling Technologies), PD-1 (clone RMP1-30; BioLegend), CD45.2 (clone 104; BioLegend), CD25
939 (clone PC61; ThermoFisher Scientific), EpCAM (clone G8.8; ThermoFisher Scientific), CD103 (clone M290;
940 BD Biosciences), CD301b (clone URA-1; BioLegend), CD80 (clone 16-10A1; ThermoFisher Scientific), CD86
941 (clone GL1; BD Biosciences), PDL-1 (clone MIH5; ThermoFisher Scientific), PDL-2 (clone MIH37; BD
942 Biosciences), BCL6 (clone K112-91; BD Biosciences), BATF (clone D7C5 rabbit; Cell Signaling Technologies),
943 Anti-GFP (goat; Novus Biologics), ICAM-1 (clone 3E2; BD Biosciences), CD207 (clone 929F3.01; Dendritics),
944 CD4 (clone GK1.5; BD Biosciences), huCD2 (clone RPA-2.10; ThermoFisher Scientific), pSTAT5 (clone
945 47/STAT5(pY694); BD Biosciences), pSTAT6 (clone J71-773.58.11; BD Biosciences), LIVE/DEAD Near-IR
946 (ThermoFisher), Chicken anti-goat (ThermoFisher) and Donkey anti-rabbit (ThermoFisher).

947

948 **Statistics**

949 Statistical analysis was performed using GraphPad Prism software. The statistical significance of
950 differences in mean values between two groups was analyzed by a two-tailed unpaired student's *t* test
951 with Welch's correction. Paired *t* tests were performed when comparing responses within the same
952 experimental tissue. In bar graphs for all figures, data is shown as mean with standard deviation.
953 **** $p < 0.0001$; *** $p < 0.001$; ** $p < 0.01$; * $p < 0.05$; $p > 0.05$ not significant (ns). Unless otherwise noted, all
954 data points represent independent LNs.

955

956 **Acknowledgments**

957 We thank current and former lab members A. de la Cruz, E. Cheng, J. Huang, J. Leal, and J. Chao, for help
958 with conceptualizing and conducting experiments. We also thank J. von Moltke and J. McGinty for help
959 with *Nippostrongylus brasiliensis* infections. Additionally, we thank M. Pepper, S. Ziegler, E. Tait Wojno,
960 and J. von Moltke for additional mice, reagents, and resources.

961

962 **Funding**

963 This study was supported by NIH grants R01AI134713 (to M.Y.G), T32AI06677 (to M.R.L-C and E.A.S) and
964 by the National Science Foundation Graduate Research Fellowship Program under grant no. NSF DGE-
965 1762114 (to M.R.L-C).

966

967 **Author contributions**

968 M.R.L-C and M.Y.G conceptualized the study. M.R.L-C performed all experiments and analyzed data. E.A.S
969 analyzed RNA sequencing data. M.R.L-C and M.Y.G wrote, edited, and reviewed the manuscript. M.Y.G.
970 supervised the project.

971
972 **References**

- 973 1. Walker, J.A., and McKenzie, A.N.J. (2018). T H 2 cell development and function. *Nat Rev*
974 *Immunol* *18*, 121-133. 10.1038/nri.2017.118.
- 975 2. van Panhuys, N., Klauschen, F., and Germain, R.N. (2014). T-cell-receptor-dependent signal
976 intensity dominantly controls CD4(+) T cell polarization In Vivo. *Immunity* *41*, 63-74.
977 10.1016/j.immuni.2014.06.003.
- 978 3. van Panhuys, N. (2016). TCR Signal Strength Alters T-DC Activation and Interaction Times and
979 Directs the Outcome of Differentiation. *Front Immunol* *7*, 6. 10.3389/fimmu.2016.00006.
- 980 4. Bhattacharyya, N.D., and Feng, C.G. (2020). Regulation of T Helper Cell Fate by TCR Signal
981 Strength. *Front Immunol* *11*, 624. 10.3389/fimmu.2020.00624.
- 982 5. Mempel, T.R., Henrickson, S.E., and Von Andrian, U.H. (2004). T-cell priming by dendritic cells in
983 lymph nodes occurs in three distinct phases. *Nature* *427*, 154-159. 10.1038/nature02238.
- 984 6. Zhu, J., Jankovic, D., Oler, A.J., Wei, G., Sharma, S., Hu, G., Guo, L., Yagi, R., Yamane, H.,
985 Punkosdy, G., et al. (2012). The transcription factor T-bet is induced by multiple pathways and
986 prevents an endogenous Th2 cell program during Th1 cell responses. *Immunity* *37*, 660-673.
987 10.1016/j.immuni.2012.09.007.
- 988 7. Tao, X., Constant, S., Jorritsma, P., and Bottomly, K. (1997). Strength of TCR signal determines
989 the costimulatory requirements for Th1 and Th2 CD4+ T cell differentiation. *J Immunol* *159*,
990 5956-5963.
- 991 8. Rulifson, I.C., Sperling, A.I., Fields, P.E., Fitch, F.W., and Bluestone, J.A. (1997). CD28
992 costimulation promotes the production of Th2 cytokines. *J Immunol* *158*, 658-665.
- 993 9. van Rijt, L.S., Vos, N., Willart, M., Kleinjan, A., Coyle, A.J., Hoogsteden, H.C., and Lambrecht, B.N.
994 (2004). Essential role of dendritic cell CD80/CD86 costimulation in the induction, but not
995 reactivation, of TH2 effector responses in a mouse model of asthma. *J Allergy Clin Immunol* *114*,
996 166-173. 10.1016/j.jaci.2004.03.044.
- 997 10. King, C.L., Stupi, R.J., Craighead, N., June, C.H., and Thyphronitis, G. (1995). CD28 activation
998 promotes Th2 subset differentiation by human CD4+ cells. *Eur J Immunol* *25*, 587-595.
999 10.1002/eji.1830250242.
- 1000 11. Gause, W.C., Chen, S.J., Greenwald, R.J., Halvorson, M.J., Lu, P., Zhou, X.D., Morris, S.C., Lee,
1001 K.P., June, C.H., Finkelman, F.D., et al. (1997). CD28 dependence of T cell differentiation to IL-4
1002 production varies with the particular type 2 immune response. *J Immunol* *158*, 4082-4087.
- 1003 12. Liu, Z., Liu, Q., Pesce, J., Anthony, R.M., Lamb, E., Whitmire, J., Hamed, H., Morimoto, M., Urban,
1004 J.F., and Gause, W.C. (2004). Requirements for the development of IL-4-producing T cells during
1005 intestinal nematode infections: what it takes to make a Th2 cell in vivo. *Immunol Rev* *201*, 57-74.
1006 10.1111/j.0105-2896.2004.00186.x.
- 1007 13. Besnard, A.G., Togbe, D., Guillou, N., Erard, F., Quesniaux, V., and Ryffel, B. (2011). IL-33-
1008 activated dendritic cells are critical for allergic airway inflammation. *Eur J Immunol* *41*, 1675-
1009 1686. 10.1002/eji.201041033.
- 1010 14. Ito, T., Wang, Y.H., Duramad, O., Hori, T., Delespesse, G.J., Watanabe, N., Qin, F.X., Yao, Z., Cao,
1011 W., and Liu, Y.J. (2005). TSLP-activated dendritic cells induce an inflammatory T helper type 2
1012 cell response through OX40 ligand. *J Exp Med* *202*, 1213-1223. 10.1084/jem.20051135.

- 1013 15. Stanbery, A.G., Shuchi Smita, Jakob von Moltke, Tait Wojno, E.D., and Ziegler, S.F. (2022). TSLP,
1014 IL-33, and IL-25: Not just for allergy and helminth infection. *J Allergy Clin Immunol* 150, 1302-
1015 1313. 10.1016/j.jaci.2022.07.003.
- 1016 16. Hung, L.Y., Tanaka, Y., Herbine, K., Pastore, C., Singh, B., Ferguson, A., Vora, N., Douglas, B.,
1017 Zullo, K., Behrens, E.M., et al. (2020). Cellular context of IL-33 expression dictates impact on anti-
1018 helminth immunity. *Sci Immunol* 5. 10.1126/sciimmunol.abc6259.
- 1019 17. León, B. (2023). A model of Th2 differentiation based on polarizing cytokine repression. *Trends*
1020 *Immunol* 44, 399-407. 10.1016/j.it.2023.04.004.
- 1021 18. Chu, D.K., Mohammed-Ali, Z., Jiménez-Saiz, R., Walker, T.D., Goncharova, S., Llop-Guevara, A.,
1022 Kong, J., Gordon, M.E., Barra, N.G., Gillgrass, A.E., et al. (2014). T helper cell IL-4 drives intestinal
1023 Th2 priming to oral peanut antigen, under the control of OX40L and independent of innate-like
1024 lymphocytes. *Mucosal Immunol* 7, 1395-1404. 10.1038/mi.2014.29.
- 1025 19. Noben-Trauth, N., Hu-Li, J., and Paul, W.E. (2000). Conventional, naive CD4+ T cells provide an
1026 initial source of IL-4 during Th2 differentiation. *J Immunol* 165, 3620-3625.
1027 10.4049/jimmunol.165.7.3620.
- 1028 20. Noben-Trauth, N., Hu-Li, J., and Paul, W.E. (2002). IL-4 secreted from individual naive CD4+ T
1029 cells acts in an autocrine manner to induce Th2 differentiation. *Eur J Immunol* 32, 1428-1433.
1030 10.1002/1521-4141(200205)32:5<1428::AID-IMMU1428>3.0.CO;2-0.
- 1031 21. Paul, W.E., and Zhu, J. (2010). How are T(H)2-type immune responses initiated and amplified?
1032 *Nat Rev Immunol* 10, 225-235. 10.1038/nri2735.
- 1033 22. Hondowicz, B.D., An, D., Schenkel, J.M., Kim, K.S., Steach, H.R., Krishnamurty, A.T., Keitany, G.J.,
1034 Garza, E.N., Fraser, K.A., Moon, J.J., et al. (2016). Interleukin-2-Dependent Allergen-Specific
1035 Tissue-Resident Memory Cells Drive Asthma. *Immunity* 44, 155-166.
1036 10.1016/j.immuni.2015.11.004.
- 1037 23. Sabatos, C.A., Doh, J., Chakravarti, S., Friedman, R.S., Pandurangi, P.G., Tooley, A.J., and
1038 Krummel, M.F. (2008). A synaptic basis for paracrine interleukin-2 signaling during homotypic T
1039 cell interaction. *Immunity* 29, 238-248. 10.1016/j.immuni.2008.05.017.
- 1040 24. DiToro, D., Winstead, C.J., Pham, D., Witte, S., Andargachew, R., Singer, J.R., Wilson, C.G., Zindl,
1041 C.L., Luther, R.J., Silberberger, D.J., et al. (2018). Differential IL-2 expression defines developmental
1042 fates of follicular versus nonfollicular helper T cells. *Science* 361. 10.1126/science.aao2933.
- 1043 25. Kumamoto, Y., Linehan, M., Weinstein, J.S., Laidlaw, B.J., Craft, J.E., and Iwasaki, A. (2013).
1044 CD301b⁺ dermal dendritic cells drive T helper 2 cell-mediated immunity. *Immunity* 39, 733-743.
1045 10.1016/j.immuni.2013.08.029.
- 1046 26. Tussiwand, R., Everts, B., Grajales-Reyes, G.E., Kretzer, N.M., Iwata, A., Bagaitkar, J., Wu, X.,
1047 Wong, R., Anderson, D.A., Murphy, T.L., et al. (2015). Klf4 expression in conventional dendritic
1048 cells is required for T helper 2 cell responses. *Immunity* 42, 916-928.
1049 10.1016/j.immuni.2015.04.017.
- 1050 27. Williams, J.W., Tjota, M.Y., Clay, B.S., Vander Lugt, B., Bandukwala, H.S., Hrusch, C.L., Decker,
1051 D.C., Blaine, K.M., Fixsen, B.R., Singh, H., et al. (2013). Transcription factor IRF4 drives dendritic
1052 cells to promote Th2 differentiation. *Nat Commun* 4, 2990. 10.1038/ncomms3990.
- 1053 28. Ochiai, S., Roediger, B., Abtin, A., Shklovskaya, E., Fazekas de St Groth, B., Yamane, H., Weninger,
1054 W., Le Gros, G., and Ronchese, F. (2014). CD326(lo)CD103(lo)CD11b(lo) dermal dendritic cells
1055 are activated by thymic stromal lymphopoietin during contact sensitization in mice. *J Immunol*
1056 193, 2504-2511. 10.4049/jimmunol.1400536.
- 1057 29. Plantinga, M., Guillems, M., Vanheerswyngheles, M., Deswarte, K., Branco-Madeira, F.,
1058 Toussaint, W., Vanhoutte, L., Neyt, K., Killeen, N., Malissen, B., et al. (2013). Conventional and
1059 monocyte-derived CD11b(+) dendritic cells initiate and maintain T helper 2 cell-mediated
1060 immunity to house dust mite allergen. *Immunity* 38, 322-335. 10.1016/j.immuni.2012.10.016.

- 1061 30. Gao, Y., Nish, S.A., Jiang, R., Hou, L., Licona-Limón, P., Weinstein, J.S., Zhao, H., and Medzhitov,
1062 R. (2013). Control of T helper 2 responses by transcription factor IRF4-dependent dendritic cells.
1063 *Immunity* 39, 722-732. 10.1016/j.immuni.2013.08.028.
- 1064 31. Krishnaswamy, J.K., Gowthaman, U., Zhang, B., Mattsson, J., Szeponik, L., Liu, D., Wu, R., White,
1065 T., Calabro, S., Xu, L., et al. (2017). Migratory CD11b + conventional dendritic cells induce T
1066 follicular helper cell-dependent antibody responses. *Sci Immunol* 2.
1067 10.1126/sciimmunol.aam9169.
- 1068 32. Li, J., Lu, E., Yi, T., and Cyster, J.G. (2016). EB12 augments Tfh cell fate by promoting interaction
1069 with IL-2- quenching dendritic cells. *Nature* 533, 110-114. 10.1038/nature17947.
- 1070 33. Connor, L.M., Tang, S.C., Cognard, E., Ochiali, S., Hilligan, K.L., Old, S.I., Pellefigues, C., White,
1071 R.F., Patel, D., Smith, A.A., et al. (2017). Th2 responses are primed by skin dendritic cells with
1072 distinct transcriptional profiles. *J Exp Med* 214, 125-142. 10.1084/jem.20160470.
- 1073 34. Hilligan, K.L., Tang, S.C., Hyde, E.J., Roussel, E., Mayer, J.U., Yang, J., Wakelin, K.A., Schmidt, A.J.,
1074 Connor, L.M., Sher, A., et al. (2020). Dermal IRF4+ dendritic cells and monocytes license CD4+ T
1075 helper cells to distinct cytokine profiles. *Nat Commun* 11, 5637. 10.1038/s41467-020-19463-9.
- 1076 35. Conejero, L., Khouili, S.C., Martínez-Cano, S., Izquierdo, H.M., Brandi, P., and Sancho, D. (2017).
1077 Lung CD103+ dendritic cells restrain allergic airway inflammation through IL-12 production. *JCI*
1078 *Insight* 2. 10.1172/jci.insight.90420.
- 1079 36. Everts, B., Tussiwand, R., Dreesen, L., Fairfax, K.C., Huang, S.C., Smith, A.M., O'Neill, C.M., Lam,
1080 W.Y., Edelson, B.T., Urban, J.F., et al. (2016). Migratory CD103+ dendritic cells suppress
1081 helminth-driven type 2 immunity through constitutive expression of IL-12. *J Exp Med* 213, 35-51.
1082 10.1084/jem.20150235.
- 1083 37. Gerner, M.Y., Torabi-Parizi, P., and Germain, R.N. (2015). Strategically localized dendritic cells
1084 promote rapid T cell responses to lymph-borne particulate antigens. *Immunity* 42, 172-185.
1085 10.1016/j.immuni.2014.12.024.
- 1086 38. Leal, J.M., Huang, J.Y., Kohli, K., Stoltzfus, C., Lyons-Cohen, M.R., Olin, B.E., Gale, M., and Gerner,
1087 M.Y. (2021). Innate cell microenvironments in lymph nodes shape the generation of T cell
1088 responses during type I inflammation. *Sci Immunol* 6. 10.1126/sciimmunol.abb9435.
- 1089 39. Groom, J.R., Richmond, J., Murooka, T.T., Sorensen, E.W., Sung, J.H., Bankert, K., von Andrian,
1090 U.H., Moon, J.J., Mempel, T.R., and Luster, A.D. (2012). CXCR3 chemokine receptor-ligand
1091 interactions in the lymph node optimize CD4+ T helper 1 cell differentiation. *Immunity* 37, 1091-
1092 1103. 10.1016/j.immuni.2012.08.016.
- 1093 40. León, B., Ballesteros-Tato, A., Browning, J.L., Dunn, R., Randall, T.D., and Lund, F.E. (2012).
1094 Regulation of T(H)2 development by CXCR5+ dendritic cells and lymphotoxin-expressing B cells.
1095 *Nat Immunol* 13, 681-690. 10.1038/ni.2309.
- 1096 41. Randolph, D.A., Huang, G., Carruthers, C.J., Bromley, L.E., and Chaplin, D.D. (1999). The role of
1097 CCR7 in TH1 and TH2 cell localization and delivery of B cell help in vivo. *Science* 286, 2159-2162.
1098 10.1126/science.286.5447.2159.
- 1099 42. Stoltzfus, C.R., Filipek, J., Gern, B.H., Olin, B.E., Leal, J.M., Wu, Y., Lyons-Cohen, M.R., Huang, J.Y.,
1100 Paz-Stoltzfus, C.L., Plumlee, C.R., et al. (2020). CytoMAP: A Spatial Analysis Toolbox Reveals
1101 Features of Myeloid Cell Organization in Lymphoid Tissues. *Cell Rep* 31, 107523.
1102 10.1016/j.celrep.2020.107523.
- 1103 43. Poholek, A.C. (2021). Tissue-Specific Contributions to Control of T Cell Immunity.
1104 *Immunohorizons* 5, 410-423. 10.4049/immunohorizons.2000103.
- 1105 44. Ataide, M.A., Knöpper, K., Cruz de Casas, P., Ugur, M., Eickhoff, S., Zou, M., Shaikh, H., Trivedi,
1106 A., Grafen, A., Yang, T., et al. (2022). Lymphatic migration of unconventional T cells promotes
1107 site-specific immunity in distinct lymph nodes. *Immunity* 55, 1813-1828.e1819.
1108 10.1016/j.immuni.2022.07.019.

- 1109 45. Mohrs, M., Shinkai, K., Mohrs, K., and Locksley, R.M. (2001). Analysis of type 2 immunity in vivo
1110 with a bicistronic IL-4 reporter. *Immunity* 15, 303-311. 10.1016/s1074-7613(01)00186-8.
- 1111 46. Gérard, A., Khan, O., Beemiller, P., Oswald, E., Hu, J., Matloubian, M., and Krummel, M.F. (2013).
1112 Secondary T cell-T cell synaptic interactions drive the differentiation of protective CD8+ T cells.
1113 *Nat Immunol* 14, 356-363. 10.1038/ni.2547.
- 1114 47. von Moltke, J., Ji, M., Liang, H.E., and Locksley, R.M. (2016). Tuft-cell-derived IL-25 regulates an
1115 intestinal ILC2-epithelial response circuit. *Nature* 529, 221-225. 10.1038/nature16161.
- 1116 48. Prout, M.S., Kyle, R.L., Ronchese, F., and Le Gros, G. (2018). IL-4 Is a Key Requirement for IL-4-
1117 and IL-4/IL-13-Expressing CD4 Th2 Subsets in Lung and Skin. *Front Immunol* 9, 1211.
1118 10.3389/fimmu.2018.01211.
- 1119 49. King, I.L., and Mohrs, M. (2009). IL-4-producing CD4+ T cells in reactive lymph nodes during
1120 helminth infection are T follicular helper cells. *J Exp Med* 206, 1001-1007.
1121 10.1084/jem.20090313.
- 1122 50. Crotty, S. (2014). T follicular helper cell differentiation, function, and roles in disease. *Immunity*
1123 41, 529-542. 10.1016/j.immuni.2014.10.004.
- 1124 51. Johnston, R.J., Choi, Y.S., Diamond, J.A., Yang, J.A., and Crotty, S. (2012). STAT5 is a potent
1125 negative regulator of TFH cell differentiation. *J Exp Med* 209, 243-250. 10.1084/jem.20111174.
- 1126 52. Ruterbusch, M., Pruner, K.B., Shehata, L., and Pepper, M. (2020). In Vivo CD4+ T Cell
1127 Differentiation and Function: Revisiting the Th1/Th2 Paradigm. *Annu Rev Immunol* 38, 705-725.
1128 10.1146/annurev-immunol-103019-085803.
- 1129 53. Fang, D., and Zhu, J. (2017). Dynamic balance between master transcription factors determines
1130 the fates and functions of CD4 T cell and innate lymphoid cell subsets. *J Exp Med* 214, 1861-
1131 1876. 10.1084/jem.20170494.
- 1132 54. Chandler, J., Prout, M., Old, S., Morgan, C., Ronchese, F., Benoist, C., and Le Gros, G. (2022).
1133 BCL6 deletion in CD4 T cells does not affect Th2 effector mediated immunity in the skin.
1134 *Immunol Cell Biol* 100, 791-804. 10.1111/imcb.12589.
- 1135 55. Johnston, R.J., Poholek, A.C., DiToro, D., Yusuf, I., Eto, D., Barnett, B., Dent, A.L., Craft, J., and
1136 Crotty, S. (2009). Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular
1137 helper cell differentiation. *Science* 325, 1006-1010. 10.1126/science.1175870.
- 1138 56. Pepper, M., Pagán, A.J., Igyártó, B.Z., Taylor, J.J., and Jenkins, M.K. (2011). Opposing signals from
1139 the Bcl6 transcription factor and the interleukin-2 receptor generate T helper 1 central and
1140 effector memory cells. *Immunity* 35, 583-595. 10.1016/j.immuni.2011.09.009.
- 1141 57. Mohrs, K., Wakil, A.E., Killeen, N., Locksley, R.M., and Mohrs, M. (2005). A two-step process for
1142 cytokine production revealed by IL-4 dual-reporter mice. *Immunity* 23, 419-429.
1143 10.1016/j.immuni.2005.09.006.
- 1144 58. Gerner, M.Y., Kastenmuller, W., Ifrim, I., Kabat, J., and Germain, R.N. (2012). Histo-cytometry: a
1145 method for highly multiplex quantitative tissue imaging analysis applied to dendritic cell subset
1146 microanatomy in lymph nodes. *Immunity* 37, 364-376. 10.1016/j.immuni.2012.07.011.
- 1147 59. Yi, T., and Cyster, J.G. (2013). EB12-mediated bridging channel positioning supports splenic
1148 dendritic cell homeostasis and particulate antigen capture. *Elife* 2, e00757. 10.7554/eLife.00757.
- 1149 60. Castellanos, C.A., Ren, X., Gonzalez, S.L., Li, H.K., Schroeder, A.W., Liang, H.E., Laidlaw, B.J., Hu,
1150 D., Mak, A.C.Y., Eng, C., et al. (2021). Lymph node-resident dendritic cells drive T H 2 cell
1151 development involving MARCH1. *Sci Immunol* 6, eabh0707. 10.1126/sciimmunol.abh0707.
- 1152 61. Yin, X., Chen, S., and Eisenbarth, S.C. (2021). Dendritic Cell Regulation of T Helper Cells. *Annu*
1153 *Rev Immunol* 39, 759-790. 10.1146/annurev-immunol-101819-025146.
- 1154 62. Hsieh, C.S., Macatonia, S.E., O'Garra, A., and Murphy, K.M. (1995). T cell genetic background
1155 determines default T helper phenotype development in vitro. *J Exp Med* 181, 713-721.
1156 10.1084/jem.181.2.713.

- 1157 63. Larson, R.P., Zimmerli, S.C., Comeau, M.R., Itano, A., Omori, M., Iseki, M., Hauser, C., and Ziegler,
1158 S.F. (2010). Dibutyl phthalate-induced thymic stromal lymphopoietin is required for Th2 contact
1159 hypersensitivity responses. *J Immunol* *184*, 2974-2984. 10.4049/jimmunol.0803478.
- 1160 64. Itano, A.A., McSorley, S.J., Reinhardt, R.L., Ehst, B.D., Ingulli, E., Rudensky, A.Y., and Jenkins, M.K.
1161 (2003). Distinct dendritic cell populations sequentially present antigen to CD4 T cells and
1162 stimulate different aspects of cell-mediated immunity. *Immunity* *19*, 47-57. 10.1016/s1074-
1163 7613(03)00175-4.
- 1164 65. Chen, L., and Flies, D.B. (2013). Molecular mechanisms of T cell co-stimulation and co-inhibition.
1165 *Nat Rev Immunol* *13*, 227-242. 10.1038/nri3405.
- 1166 66. Acuto, O., and Michel, F. (2003). CD28-mediated co-stimulation: a quantitative support for TCR
1167 signalling. *Nat Rev Immunol* *3*, 939-951. 10.1038/nri1248.
- 1168 67. Huber, M., and Lohoff, M. (2014). IRF4 at the crossroads of effector T-cell fate decision. *Eur J*
1169 *Immunol* *44*, 1886-1895. 10.1002/eji.201344279.
- 1170 68. Iwata, A., Durai, V., Tussiwand, R., Briseño, C.G., Wu, X., Grajales-Reyes, G.E., Egawa, T., Murphy,
1171 T.L., and Murphy, K.M. (2017). Quality of TCR signaling determined by differential affinities of
1172 enhancers for the composite BATF-IRF4 transcription factor complex. *Nat Immunol* *18*, 563-572.
1173 10.1038/ni.3714.
- 1174 69. Krishnamoorthy, V., Kannanganat, S., Maienschein-Cline, M., Cook, S.L., Chen, J., Bahroos, N.,
1175 Sievert, E., Corse, E., Chong, A., and Sciammas, R. (2017). The IRF4 Gene Regulatory Module
1176 Functions as a Read-Write Integrator to Dynamically Coordinate T Helper Cell Fate. *Immunity* *47*,
1177 481-497.e487. 10.1016/j.immuni.2017.09.001.
- 1178 70. Kuwahara, M., Ise, W., Ochi, M., Suzuki, J., Kometani, K., Maruyama, S., Izumoto, M.,
1179 Matsumoto, A., Takemori, N., Takemori, A., et al. (2016). Bach2-Batf interactions control Th2-
1180 type immune response by regulating the IL-4 amplification loop. *Nat Commun* *7*, 12596.
1181 10.1038/ncomms12596.
- 1182 71. Li, P., Spolski, R., Liao, W., Wang, L., Murphy, T.L., Murphy, K.M., and Leonard, W.J. (2012).
1183 BATF-JUN is critical for IRF4-mediated transcription in T cells. *Nature* *490*, 543-546.
1184 10.1038/nature11530.
- 1185 72. Lohoff, M., Mittrücker, H.W., Pechtl, S., Bischof, S., Sommer, F., Kock, S., Ferrick, D.A., Duncan,
1186 G.S., Gessner, A., and Mak, T.W. (2002). Dysregulated T helper cell differentiation in the absence
1187 of interferon regulatory factor 4. *Proc Natl Acad Sci U S A* *99*, 11808-11812.
1188 10.1073/pnas.182425099.
- 1189 73. Rengarajan, J., Mowen, K.A., McBride, K.D., Smith, E.D., Singh, H., and Glimcher, L.H. (2002).
1190 Interferon regulatory factor 4 (IRF4) interacts with NFATc2 to modulate interleukin 4 gene
1191 expression. *J Exp Med* *195*, 1003-1012. 10.1084/jem.20011128.
- 1192 74. Bao, K., Carr, T., Wu, J., Barclay, W., Jin, J., Ciofani, M., and Reinhardt, R.L. (2016). BATF
1193 Modulates the Th2 Locus Control Region and Regulates CD4+ T Cell Fate during Antihelminth
1194 Immunity. *J Immunol* *197*, 4371-4381. 10.4049/jimmunol.1601371.
- 1195 75. Sahoo, A., Alekseev, A., Tanaka, K., Obertas, L., Lerman, B., Haymaker, C., Clise-Dwyer, K.,
1196 McMurray, J.S., and Nurieva, R. (2015). Batf is important for IL-4 expression in T follicular helper
1197 cells. *Nat Commun* *6*, 7997. 10.1038/ncomms8997.
- 1198 76. Gérard, A., Cope, A.P., Kemper, C., Alon, R., and Köchl, R. (2021). LFA-1 in T cell priming,
1199 differentiation, and effector functions. *Trends Immunol* *42*, 706-722. 10.1016/j.it.2021.06.004.
- 1200 77. Wang, Y., Shibuya, K., Yamashita, Y., Shirakawa, J., Shibata, K., Kai, H., Yokosuka, T., Saito, T.,
1201 Honda, S., Tahara-Hanaoka, S., and Shibuya, A. (2008). LFA-1 decreases the antigen dose for T
1202 cell activation in vivo. *Int Immunol* *20*, 1119-1127. 10.1093/intimm/dxn070.
- 1203 78. Krummel, M.F., Mahale, J.N., Uhl, L.F.K., Hardison, E.A., Mujal, A.M., Mazet, J.M., Weber, R.J.,
1204 Gartner, Z.J., and Gérard, A. (2018). Paracrine costimulation of IFN- γ signaling by integrins

1205 modulates CD8 T cell differentiation. *Proc Natl Acad Sci U S A* *115*, 11585-11590.
 1206 10.1073/pnas.1804556115.
 1207 79. Liao, W., Schones, D.E., Oh, J., Cui, Y., Cui, K., Roh, T.Y., Zhao, K., and Leonard, W.J. (2008).
 1208 Priming for T helper type 2 differentiation by interleukin 2-mediated induction of interleukin 4
 1209 receptor alpha-chain expression. *Nat Immunol* *9*, 1288-1296. 10.1038/ni.1656.
 1210 80. Cayrol, C., Duval, A., Schmitt, P., Roga, S., Camus, M., Stella, A., Bulet-Schiltz, O., Gonzalez-de-
 1211 Peredo, A., and Girard, J.P. (2018). Environmental allergens induce allergic inflammation
 1212 through proteolytic maturation of IL-33. *Nat Immunol* *19*, 375-385. 10.1038/s41590-018-0067-5.
 1213 81. von Moltke, J., and Pepper, M. (2018). Sentinels of the Type 2 Immune Response. *Trends*
 1214 *Immunol* *39*, 99-111. 10.1016/j.it.2017.10.004.
 1215 82. Halim, T.Y., Hwang, Y.Y., Scanlon, S.T., Zaghoulani, H., Garbi, N., Fallon, P.G., and McKenzie, A.N.
 1216 (2016). Group 2 innate lymphoid cells license dendritic cells to potentiate memory TH2 cell
 1217 responses. *Nat Immunol* *17*, 57-64. 10.1038/ni.3294.
 1218 83. De Koker, S., Van Hoecke, L., De Beuckelaer, A., Roose, K., Deswarte, K., Willart, M.A., Bogaert,
 1219 P., Naessens, T., De Geest, B.G., Saelens, X., et al. (2017). Inflammatory monocytes regulate Th1
 1220 oriented immunity to CpG adjuvanted protein vaccines through production of IL-12. *Sci Rep* *7*,
 1221 5986. 10.1038/s41598-017-06236-6.
 1222 84. Zhou, B., Comeau, M.R., De Smedt, T., Liggitt, H.D., Dahl, M.E., Lewis, D.B., Gyarmati, D., Aye, T.,
 1223 Campbell, D.J., and Ziegler, S.F. (2005). Thymic stromal lymphopoietin as a key initiator of
 1224 allergic airway inflammation in mice. *Nat Immunol* *6*, 1047-1053. 10.1038/ni1247.
 1225 85. Liu, Z., Liu, Q., Hamed, H., Anthony, R.M., Foster, A., Finkelman, F.D., Urban, J.F., and Gause,
 1226 W.C. (2005). IL-2 and autocrine IL-4 drive the in vivo development of antigen-specific Th2 T cells
 1227 elicited by nematode parasites. *J Immunol* *174*, 2242-2249. 10.4049/jimmunol.174.4.2242.
 1228 86. Fraser, J.D., Irving, B.A., Crabtree, G.R., and Weiss, A. (1991). Regulation of interleukin-2 gene
 1229 enhancer activity by the T cell accessory molecule CD28. *Science* *251*, 313-316.
 1230 10.1126/science.1846244.
 1231 87. June, C.H., Ledbetter, J.A., Gillespie, M.M., Lindsten, T., and Thompson, C.B. (1987). T-cell
 1232 proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2
 1233 gene expression. *Mol Cell Biol* *7*, 4472-4481. 10.1128/mcb.7.12.4472-4481.1987.
 1234 88. Crotty, S. (2011). Follicular helper CD4 T cells (TFH). *Annu Rev Immunol* *29*, 621-663.
 1235 10.1146/annurev-immunol-031210-101400.
 1236 89. Noben-Trauth, N., Shultz, L.D., Brombacher, F., Urban, J.F., Gu, H., and Paul, W.E. (1997). An
 1237 interleukin 4 (IL-4)-independent pathway for CD4+ T cell IL-4 production is revealed in IL-4
 1238 receptor-deficient mice. *Proc Natl Acad Sci U S A* *94*, 10838-10843. 10.1073/pnas.94.20.10838.
 1239 90. Perona-Wright, G., Mohrs, K., and Mohrs, M. (2010). Sustained signaling by canonical helper T
 1240 cell cytokines throughout the reactive lymph node. *Nat Immunol* *11*, 520-526. 10.1038/ni.1866.
 1241 91. Duan, L., Liu, D., Chen, H., Mintz, M.A., Chou, M.Y., Kotov, D.I., Xu, Y., An, J., Laidlaw, B.J., and
 1242 Cyster, J.G. (2021). Follicular dendritic cells restrict interleukin-4 availability in germinal centers
 1243 and foster memory B cell generation. *Immunity* *54*, 2256-2272.e2256.
 1244 10.1016/j.immuni.2021.08.028.
 1245 92. Huse, M., Lillemeier, B.F., Kuhns, M.S., Chen, D.S., and Davis, M.M. (2006). T cells use two
 1246 directionally distinct pathways for cytokine secretion. *Nat Immunol* *7*, 247-255. 10.1038/ni1304.
 1247 93. Steinfeldt, S., Andersen, J.F., Cannons, J.L., Feng, C.G., Joshi, M., Dwyer, D., Caspar, P.,
 1248 Schwartzberg, P.L., Sher, A., and Jankovic, D. (2009). The major component in schistosome eggs
 1249 responsible for conditioning dendritic cells for Th2 polarization is a T2 ribonuclease (omega-1). *J*
 1250 *Exp Med* *206*, 1681-1690. 10.1084/jem.20082462.

- 1251 94. Szeto, A.C.H., Ferreira, A.C.F., Mannion, J., Clark, P.A., Sivasubramaniam, M., Heycock, M.W.D.,
1252 Crisp, A., Jolin, H.E., Kozik, P., Knolle, M.D., and McKenzie, A.N.J. (2023). An $\alpha\beta 3$ integrin
1253 checkpoint is critical for efficient T. *Nat Immunol* 24, 123-135. 10.1038/s41590-022-01378-w.
- 1254 95. Gaylo-Moynihan, A., Prizant, H., Popović, M., Fernandes, N.R.J., Anderson, C.S., Chiou, K.K., Bell,
1255 H., Schrock, D.C., Schumacher, J., Capece, T., et al. (2019). Programming of Distinct Chemokine-
1256 Dependent and -Independent Search Strategies for Th1 and Th2 Cells Optimizes Function at
1257 Inflamed Sites. *Immunity* 51, 298-309.e296. 10.1016/j.immuni.2019.06.026.
- 1258 96. Mayer, J.U., Hilligan, K.L., Chandler, J.S., Eccles, D.A., Old, S.I., Domingues, R.G., Yang, J., Webb,
1259 G.R., Munoz-Erazo, L., Hyde, E.J., et al. (2021). Homeostatic IL-13 in healthy skin directs dendritic
1260 cell differentiation to promote T. *Nat Immunol* 22, 1538-1550. 10.1038/s41590-021-01067-0.
- 1261 97. Ricardo-Gonzalez, R.R., Van Dyken, S.J., Schneider, C., Lee, J., Nussbaum, J.C., Liang, H.E., Vaka,
1262 D., Eckalbar, W.L., Molofsky, A.B., Erle, D.J., and Locksley, R.M. (2018). Tissue signals imprint
1263 ILC2 identity with anticipatory function. *Nat Immunol* 19, 1093-1099. 10.1038/s41590-018-
1264 0201-4.
- 1265 98. Halim, T.Y., Steer, C.A., Mathä, L., Gold, M.J., Martinez-Gonzalez, I., McNagny, K.M., McKenzie,
1266 A.N., and Takei, F. (2014). Group 2 innate lymphoid cells are critical for the initiation of adaptive
1267 T helper 2 cell-mediated allergic lung inflammation. *Immunity* 40, 425-435.
1268 10.1016/j.immuni.2014.01.011.
- 1269 99. Perner, C., Flayer, C.H., Zhu, X., Aderhold, P.A., Dewan, Z.N.A., Voisin, T., Camire, R.B., Chow,
1270 O.A., Chiu, I.M., and Sokol, C.L. (2020). Substance P Release by Sensory Neurons Triggers
1271 Dendritic Cell Migration and Initiates the Type-2 Immune Response to Allergens. *Immunity* 53,
1272 1063-1077.e1067. 10.1016/j.immuni.2020.10.001.
- 1273 100. Carroll-Portillo, A., Cannon, J.L., te Riet, J., Holmes, A., Kawakami, Y., Kawakami, T., Cambi, A.,
1274 and Lidke, D.S. (2015). Mast cells and dendritic cells form synapses that facilitate antigen
1275 transfer for T cell activation. *J Cell Biol* 210, 851-864. 10.1083/jcb.201412074.
- 1276 101. Sumpster, T.L., Balmert, S.C., and Kaplan, D.H. (2019). Cutaneous immune responses mediated by
1277 dendritic cells and mast cells. *JCI Insight* 4. 10.1172/jci.insight.123947.
- 1278 102. Suto, H., Nakae, S., Kakurai, M., Sedgwick, J.D., Tsai, M., and Galli, S.J. (2006). Mast cell-
1279 associated TNF promotes dendritic cell migration. *J Immunol* 176, 4102-4112.
1280 10.4049/jimmunol.176.7.4102.
- 1281 103. Tong, P.L., Roediger, B., Kolesnikoff, N., Biro, M., Tay, S.S., Jain, R., Shaw, L.E., Grimbaldston,
1282 M.A., and Weninger, W. (2015). The skin immune atlas: three-dimensional analysis of cutaneous
1283 leukocyte subsets by multiphoton microscopy. *J Invest Dermatol* 135, 84-93.
1284 10.1038/jid.2014.289.
- 1285 104. Powell, D. (2019). drpowell/degust 4.1.1 (4.1.1). Zenodo.
- 1286 105. Liao, Y., Wang, J., Jaehnig, E.J., Shi, Z., and Zhang, B. (2019). WebGestalt 2019: gene set analysis
1287 toolkit with revamped UIs and APIs. *Nucleic Acids Res* 47, W199-W205. 10.1093/nar/gkz401.
- 1288 106. Taverna, F., Goveia, J., Karakach, T.K., Khan, S., Rohlenova, K., Treps, L., Subramanian, A.,
1289 Schoonjans, L., Dewerchin, M., Eelen, G., and Carmeliet, P. (2020). BIOMEX: an interactive
1290 workflow for (single cell) omics data interpretation and visualization. *Nucleic Acids Res* 48,
1291 W385-W394. 10.1093/nar/gkaa332.
- 1292 107. Kucukural, A., Yukselen, O., Ozata, D.M., Moore, M.J., and Garber, M. (2019). DEBrowser:
1293 interactive differential expression analysis and visualization tool for count data. *BMC Genomics*
1294 20. 10.1186/s12864-018-5362-x.

1295